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Widespread drug resistance, loss of efficacy and toxicity has limited the full utilization of 
the current available drugs against malaria and other parasitic diseases. This necessitates 
the development of new drugs. Meanwhile, the cysteine protease family of enzymes has 
been identified as potential targets for new modes of chemotherapy due to the numerous 
critical roles they play in the disease-causing agents. 
In this project, a non-peptidic and low molecular weight isatin (indole-2, 3-dione) 
possessing a wide range of pharmacological properties was used as a scaffold to which 
different moeities were appended. Potential inhibitors of parasitic cysteine proteases and 
three strains of P. falciparum were identified from synthesized libraries of compounds. 
Various N-substituted isatin derivatives were synthesized by KF/Ah03-mediated reaction 
of isatins with an alkyl, acyl or sulfonyl halide. A series of isatin-3-thiosemicarbazones 
were prepared by condensation of isatin I substituted isatins with thiosemicarbazide, and 
also a series of isatin-based Schiff and Mannich bases were prepared by reacting selected 
isatin-3-thiosemicarbazones with formaldehyde and appropriate secondary amines. To 
compare the effects of replacing the Mannich bases, a similar series of aminoquinoline-
ethylene isatin-based derivatives were then synthesized. The synthesis was accomplished 
by condensation of quinoline-ethylene ketone forms with thiosemicarbazide. All 
synthesized compound were obtained in reasonable to excellent yields and characterized 
by spectroscopic and analytical techniques. 
These synthesized compounds were then subsequently tested for inhibition of cysteine 
proteases (falcipaill-2, cruzain and rhodesain) and also for in vitro activity against strains 
of the parasitic protozoa P. falciparum (chloroquine-sensitive D 1 0 and chloroquine-
resistant W2 and Kl). The structure-activity relationships (SARs) among the classes of 
compounds for inhibition offalcipain-2, cruzain, rhodesain and P. falciparwn malaria 
parasites were studied. Compound N-biphenyl-2-yl-5-metlzyl- J H-indole-2, 3-dione (S7f) 
in the class of N-substituted isatin derivatives showed good inhibitory activity against 
falcipain-2 and cruzain. Another compound from the thiosemicarbazones found to be 
very active was 5-chloro-7-isatin-3-thiosemicarbazone (6Sf), with ICso values of 10 11M 











The quinoline-ethylene isatin thiosemicarbazone derivatives gave optimal in vitro 
antimalarial activity with ~ 1-[2-(7 -chloro-quinol-4-ylamino )-ethyl] -5-methyl-l H-idole-
2.3-dione-3-thiosemicarbazone (71 b) showing excellent activity against a chloroquine-
resistant P. falciparum (W2) strain (lC50 = 0.051 JlM) substantially lower than 
chloroquine in W2 (IC5o 0.24 ~lM). Similarily, 5-ch!oro-N
1-[2-(7-chloro-quinol-4-
ylamillo}-ethylJ-IH-indole-2.3-dione (71c) showed high activity against another 
chloroquine-resistant P. falciparum (Kl) strain (IC5o = 0.054 JlM). The IC50 of 
chloroquine in K 1 was 0.312 JlM. This did not correlate with the inhibitory potency 
against the P. falciparum cysteine protease falcipain-2. The lack of correlation between 
inhibitory activity against falcipain-2 and the three malaria parasite strains suggests that 
falcipaill-2 is not the target in quinoline-ethylene isatin thiosemicarbazone inhibitors. 
Alternatively, these metal-chelating compounds may be metal (Fe-")-interactive 
inhibitors ofj'alcipain-2 under the pro-oxidative intra-erythrocytic conditions of oxidative 
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1.1 Introduction to Parasitic Diseases 
Parasites, a group of microorganisms of the protista kingdom, have played a dominant role in 
the history of human diseases. Not only are parasites common in humans, they are also found 
among plants and animal groups where they live for survival and completion of their life cycles. 
The animal-like unicellular parasites also known as protozoa are of medical importance because 
of their ability to cause severe organ dysfunctions in the hosts. Examples of protozoan parasites 
include Entamoeba (amoebiasis/amoebic dysentery), Trypanosomes (African trypanosomiasis, 
Chagas disease), Balantidium (colitis, diarrhea) and Plasmodium (malaria). [I] 
Globally, parasitic diseases such as Trypanosomiasis, Malaria and Leishmaniasiss are major 
causes of illness today particularly in the developing tropical and subtropical countries, [2] and 
some sections of the United States. [3] In the developing countries, poverty and climate are the 
key contributors to the rapid transmission and prevalence of the diseases. In the 1998 World 
Health Organization report, of a global total of 52.2 million deaths, 17.3 million were due to 
infectious and parasitic diseases. [4] The burden of parasitic diseases remains a major concern as 
recent estimates stand at 273 million infections each year for malaria; 1.2 million for African 
trypanosomiasis and 1.7 million for leishmaniasis. On the other hand, schistosomiasis and 
filariasis were reported to affect 200 million and 120 million people respectively. [5] 
For most of the parasitic diseases, there are adequate drugs available to completely treat these 
infections. The major drawback faced with these drugs includes loss of efficacy, unacceptable 
toxicity and widespread drug resistance. Socio-economie factors have further added to the 
problem of antiparasitic chemotherapy. The diseases are mostly prevalent in poor and highly 
indebted nations where drug research and development costs are out of reach. [61 On the other 
hand, the access to available drugs, and more general to health services, is more and more 
restricted on economical grounds. Coupled with the profit driven trends in the pharmaceutical 
industries in the western world today, the tropical diseases always remain unattended to. [7] 
Within the context of parasitic infections, malaria is the key parasitic disease and was the main 












Malaria, a deadly fever probably among the oldest known to mankind, is caused by plasmodium 
protozoa and transmitted via bites by female mosquitoes belonging to the Anopheles species. 
Malaria is now mainly confined to Africa, Asia and Latin America. It kills between I and 1.5 
million people each year. The four species of Plasmodium parasite responsible for causing 
human malaria are, Plasmodium Jalciparum. Plasmodium vivax. Plasmodium ovale, and 
Plasmodium ma/ariae, with the Plasmodium jalciparum strain being responsible for most 
fatalities. [8J P. jalciparum is the prevalent species in sub-Sahara Africa accounting in large part 
for the extremely high mortality in this region. [9] P. vivax is second cause of malaria death, it is 
also known to cause gradual health deterioration as it remains in the body for a long time. P. 
vivax is the predominant malaria species in most of Asia, Oceania, North Africa, Central and 
South America. 
In malaria areas, women and children are most vulnerable and at the highest risk of morbidity 
and mortality. Children die in their first or second year of their life before they have adequately 
developed immunity. As for women, they are at risk during the first pregnancy when their 
immunity is impaired and so susceptible to P. jalciparum malaria. 
Malaria has 3 prime ways in which it can cause death in individuals. 
i). presence of seizures or coma in case of cerebral malaria. 
ii). Severe anaemia due to excessive breakdown of red blood cells. 
iii). High body temperatures that is accompanied by erythrocytic phase of the ailment. 
Malaria is known to cause long-term disabilities in children who frequently get the fever or 
those who survive cerebral form of malaria. The most notable effects in survivals include 
learning impairment, mental disabilities due to brain damage, epilepsy and spasticity. (!O] 
F or a better understanding of the pathogenesis and the current chemotherapies, it is necessary to 
look at the life cycle of the malaria parasite. 
1.2.1 Life Cycle of the Malaria Parasite 
The life cycle of the malaria parasite involves two stages: a sexual reproductive stage which 
occurs in the mosquito, and an asexual reproduction stage, which takes place in the human host. 
Ill] The latter can be distinctively categorized as exoerythrocytic (liver) and the erythrocytic 
(blood) phases. The human part of the cycle is responsible for the disease pathology and target 
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Figure I. A representation of the P.falciparum life cycle. [12] 
Introduction 
Figure 1 depicts the life cycle of Pfalciparum (12) whose basic features are identical to the other 
Plasmodium species. The cycle starts when sporozoites are injected in human peripheral 
circulation during the blood-meal of an infected anopheline mosquito (a). Within minutes they 
migrate to the hepatocytes in the liver (b) and undergo asexual mUltiplication yielding 
merozoites, a new form of parasites within 1 to 2 weeks. Infected hepatocytes rupture to release 
the merozoites into the blood stream (c) to continue with the cycle. Merozoites then invade the 
erythrocytes (d) where they progressively break down human hemoglobin into amino acids 
destroying the erythrocytes. Using the amino acid, merozoites then either divide or differentiate 
into male (microgametocytes) and female (macrogametocyte) which either invades other red 
blood cells (t) to continue the erythrocytic cycle ( e) or re-enter the blood stream (g) eventually 
taken up by a feeding Anopheles sp. mosquito thus completing the cycle (h). This erythrocytic 
stage of the parasitic cycle is thought to be responsible for the periodic clinical manifestations of 












1.2.2 History and Limitation of Current Antimalarials 
Malaria has a long-standing history of chemotherapy that goes back to more than 350 years ago 
when quinine was first used in treating the fever. Several classes of antimalarial drugs with 
different structural features and targeting different stages of the malaria parasite's life cycle 
have been developed in the last century (fig. 2).[14] Amongst the most successful antimalarial 
drugs ever used is the chloroquine, I (fig 2) which was discovered in 1934 by a German 
scientist and consequently launched in 1944. 
chloroquine I amodiaquine 2 quinine 3 
mefloquine 4 primaquine 5 tafenoquine 6 
OH 
CI 
halofantrine 7 proguani19 
trioxaquine 10 artermisinin lOa 












For many years chloroquine has proved to be a highly effective, safe [15], and affordable drug for 
the treatment and prophylaxis of malaria mainly in Southeast Asia, portions of South America, 
and much of Sub-Sahara Africa. Despite the widespread resistance to chloroquine, the drug is 
still active against the erythrocytic stage of P. ma/ariae, P. vivax and even chloroquine-sensitive 
P. falciparum and P. vivax species. Chloroquine transverses through the membranes of the 
parasite and moves against a pH gradient subsequently accumulating in the acidic parasite's 
food vacuole by a pH trapping mechanism. Accumulation of chloroquine is facilitated by the 
weak base properties of the drug. At neutral conditions, chloroquine diffuses through the 
membranes while at acidic pH of the vacuole, it is protonated and trapped. However, the 
involvement of the drug in inhibitory process is not clear; presumably it interferes with heme 
polymerization leading to accumulation of toxic heme that becomes fatal to the parasite. [16-18] 
Serious adverse effects of chloroquine are rare, sometimes headaches, nausea, vomiting and 
gastrointestinal symptoms may be experienced with its administration. 
Amodiaquine (2) (fig 2) an analog of chloroquine was used in the treatment and prevention of 
uncomplicated malaria and some chloroquine-resistant strains. [19] It was introduced about 40 
years ago as an alternative to chloroquine. Nowadays, amodiaquine is not recommended due to 
some toxic side effects such as agranulocytosis and hepatotoxicity. 
Quinine (3) (fig 2), a natural alkaloid, is the longest serving antimalarial discovered in the 1 i h 
century in South Ameriea by Augustinian monks. [20, 21] It is available commercially and has 
excellent activity against all Plasmodium malaria cases. The mode of action quinine is similar to 
other quinolines group of drugs as they all bind strongly to haematin, and form complexes 
which are toxic to the malarial parasite. [22J However, quinine is associated with toxicity 
resulting from repeated doses. Symptoms (also known as cinchonisms) include tinnitus, 
headache, deafness, and occasionally, anaphylactoid shock are characteristic of extensive 
quinine use. [23] 
Metloquine (4) (fig 2), a structural analog of quinine, is a relatively new drug used for treatment 
and as a prophylactic. It is a potent long-acting schizonticide active against P. falciparum 
resistant to 4-aminoquinoline and folate antangonist drugs. Neuropsychiatric adverse reactions 
have been reported that include anxiety disorders, hallucinations, sleeping disturbances, 
convulsions and acute brain syndromes. [24] Sporadic cases of mefloquine resistance have been 
reported from Thailand [25] and Kenya. [26] 
Primaquine (5) (fig 2) and tafenoquine (6) (fig 2) belong to the 8-aminoquinoline class of 












treating P. Jalciparum malaria. The drug is instead used to eradicate early stages of P. 
Jalciparum and hypnozoites of P. vivax and P. ova/e. [271 Primaquine acts by interfering with 
mitochondrial functions of Plasmodium. Toxic effects of the drug include mild anemia, cyanosis 
and haemolysis. [28] Tafenoquine is a long-acting 8-aminoquinoline with a half-life of 2weeks 
and used by all short-time visitors to malarial areas to prevent the risk of P. Jalciparum malaria 
infections. [29] Tafenoquine is commonly used for treating multidrug-resistant P. Jalciparum 
malaria, particularly in combination with artemisinin derivatives. 
Folate antagonists are a new group of drugs also known as folate blockers. They act on 
erythrocytic P. Jalciparum, but not sporozoites or hypnozoites. The drugs (pyrimethamine 8 and 
proguanil 9) (fig 2) inhibit preferentially the dihydrofolate reductase (OHFR) necessary for 
synthesis of tetrahydrofolate, a precursor in the parasite DNA synthesis, whilst (sulfones and 
sulfonamides) inhibit dihydro-pteroate synthetase (OHPS) enzymes of malaria parasites. 
Widespread resistance of parasites to the drug has been reported in most malaria-endemic areas. 
[30] Furthermore, high cost of the drug ($40 per treatment) and reported side effects (severe skin 
and mucous membrane reactions) further hampers full utilization of this class of drugs. [31 - 33J 
Artemisinin (lOa) (fig 2) is an active ingredient of the Chinese herb quinghao and has been 
used in the cure for fevers and malaria over the past two-three decades. [34 - 38] It is the fastest 
active antimalarial drug that exists in several forms including artemether, arteether, and 
artesunate. It has been used in the treatment of severe eases of malaria in combination with other 
drugs like mefloquine, sulfadoxine-pyrimethamine and benflumetol mainly because of its short 
half-life (3-5 hours). [39] The drugs are known to generate free radicals which are toxic to the 
parasites. 
Recently a senes of trioxaquine (10) (fig 2) were reported as potential agents against 
chloroquine-resistant malaria. Trioxaquine combines an artemisinin and the basic 4-
aminoquinoline moiety of chloroquine which presumably is necessary for concentration in the 
acidic food vacuole and binding to heme. These molecules were designed with an effort to delay 
or prevent the early development of resistance and increasing the efficacy of the compound. The 
drug was tested in vitro against chloroquine-sensitive and chloroquine-resistant strains of 
Pfalciparum all with ICso values below 30nM. Trioxaquine is highly active against 
Chloroquine-resistant strains (ICso 21 nM) compared to 116 nM for chloroquine. These 
encouraging results indicate that the use of bitherapeutic approach may be the best and 












1.2.3 Drug Resistance 
Increasing resistance of malaria parasites to drugs is threatening to undermine efforts to treat the 
disease in endemic areas and is a major source of concern. Clinically, drug resistance is the 
ability of the malaria parasite (P. Jalciparum and P. vi vax) to mutate, thus restraining the power 
of conventional antimalarial drugs to fight it. This, ultimately, allows the parasite's rapid 
replication. 
The emergence and spread of resistance are not clear though studies indicate several factors , 
including abuse, underuse or misuse of antimicrobials, poor patient compliance, poor quality of 
available drugs and spontaneously-occurring gene mutation that affect the structure and activity 
at the drug target in the malaria parasite P. Jalciparum and P. vivax. The latter is more 
pronounced and affects the accessibility of the drug to that target. Antifolates, for example, act 
by inhibiting folate biosynthetic pathway in dihydropteroate synthetase (dhps) and dihydrofolate 
reductase (dhfr) . Resistance of parasites against proguanils (dhfr inhibitors) is attributed to a 
simple single mutations in the dhfr enzyme, [40] while resistance to sulfonamides (dhps 
inhibitors) is due to a similar mutations in the corresponding gene. [41] On the other hand, studies 
on chloroquine resistance is attributed to mutations in the pJcrt (P. Jalciparum chloroquine 
resistance transporter) gene located on the swface of the parasite food vacuole and Pghl (P. 
glycoprotein homolog). [42] Pghl is actually implicated in the development of resistance in other 
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Figure 3. Decline in response to Antimalarial Drugs. 
7 
The global picture of reduced susceptibility of 
p , Jalciparum to various antimalarials is 
provided in Figure 3 and this underlines the 
importance of development of new and better 
drugs that are active against the parasites. A 
change in the present strategy of antimalarial 
chemotherapy is needed because with the 
current trend of declining antimalarial 












1:3 Other parasitic diseases 
While there might be some evidence to suggest that compounds found to be antimalarials can 
also act against other protozoan parasites, for example, Trypanosoma cruzi, Trypanosoma 
brucei and Leishmania, it is necessary to briefly look these agents and their associated parasitic 
diseases although the main focus of the project is on malaria. 
Human African trypanosomiasis, HAT, also known as (sleeping sickness) is a systematic and 
central nervous system (CNS) infection. Two distinct species of flagellated protozoa 
(trypanosomes) responsible for the pathological conditions are Trypanosoma brucei rhodesiense 
(occurs in East and Southern Africa) and Trypanosoma brucei gambiense (occurs in West and 
Central Africa). The former is responsible for acute (blood forms), whilst the latter causes 
chronic forms (tissue forms) of the disease. [43] The only drugs used to treat African 
Trypanomiasis are, melarsoprol, pentamidine 11 (fig.4) and eflornithine. Melarsoprol is 
restricted in use due to toxicity and adverse side effects including chest pain, abdominal pain 
and phlebitis. [44J However, melarsoprol remains the drug of choice for treating the chronic 
disease stage. 
Chagas disease is caused by a parasite of the species Trypanosoma cruzi (different from the 
fellow kinetoplastid species of Leishmania and Trypanosoma brucei species families). This is 
prevalent in Latin and South America where conditions favour the growth of reduviid insects 
(also called kissing bugs). The protozoan parasite (T cruzi), enters the human body through 
broken skin from faeces of the bugs. Like HAT, Chagas disease also manifests itself in acute 
(mild symptoms of fevers and swelling of glands) and chronic forms. The chronic stage is the 
most fatal as it affects heart muscle, oesophagus and lower intestine causing severe damage. [45] 
Nifurtimox 12 (fig. 4) and benznidazole 13 (fig.4) are efIective against the acute stages of the 
disease and are inadequate to treat the chronic infections. 
Leishmaniasis is transmitted by the bite of some speCIes of sand nies. The disease most 
commonly manifests either in a cutaneous (skin) form or in a visceral (intcrnal organ) forms. 
The 75% of cases that are reported are in Latin America and some areas of South America. 
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Background and Rationale 
CHAPTER 2 
BACKGROUND AND RATIONALE: CYSTEINE PROTEASES AND 
CHEMISTRY OF ISATIN 
2.1 CYSTEINE PROTEASES AND THEIR INHIBITORS 
2.1.1 Introduction 
As mentioned earlier (in Chapter 1), the current chemotherapy for malaria and other parasitic 
diseases is limited in terms of efficacy, toxicity and resistance. Furthermore, the high cost of 
current drugs is making it difficult to treat parasitic infections. Hence, there is an urgent need for 
new treatment approaches that are safe, effective and cheap. 
Biochemical pathways found in parasites have provided vital insights in finding alternative 
routes to current therapies. Enzymes of these pathways are thought to be particularly ideal 
targets in treatment of parasitic diseases. For example, cysteine proteases, a class of enzymes 
involved in numerous biological and biochemical processes in parasites, have been reported to 
be an attractive target in the fight against malaria. [46] In antimalarial chemotherapy, the current 
focus is particularly on falcipains-(2 and 3) cysteine proteases that are located inside the 
parasitic acidic food vacuole that mediate hemoglobin hydrolysis and are crucial to the survival 
of the malaria parasite. Previous studies have shown that peptidyl vinyl sulfones effectively 
inhibit falcipain-2 or 3 and exhibited strong antimalarial effects in vitro and in vivo. [46. 471 In 
separate studies, peptidyl and non-peptidyl inhibitors of the major cysteine proteases of 
trypanosomes killed T brucei [48] and T cruzi in vitro and in vivo. [49] The results clearly suggest 
that compounds directed against cysteine proteases may be promising antiparasitic drugs. 
2.1.2 Cysteine Proteases 
Cysteine proteases are proteolytic enzymes that utilize the cysteine thiol for catalytic activity. 
These enzymes catalyse the cleavage of amide linkages in proteins and peptides. Generally, the 
enzymes can be categorized based on occurence as plant proteases, mammalian lysosomal 
proteases, viral, fungi or bacterial proteases. [50, 5J] Proteases clan CA (papain-like) and family 
Clare of medical importance and account for more than half of all cysteine proteases. These 
include the cathepsins B [52] and L [53] (involved in cancer), cathepsin K [54] (involved in bone 
degradation) as well as parasitic proteases (associated with Chagas disease, malaria and 
leishmaniasis). Enzymes of family C14 (the caspases) have gained attention because of their 
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require Ca2+ and have been implicated in a number of diseases such as neurological disorders 
and Alzheimer's disease. [51] 
2.1.3 Cysteine Proteases of Parasitic Organisms 
Parasitic protozoa contain numerous cysteine proteases all so crucial to the life cycle of the 
organisms. More recently, a good number of these enzymes have been identified and 
characterized. Among the most important are cysteine proteases in P .Jalciparum, Trypanosoma 
cruzl, Trypanosoma brucei rhodesiense and Trypanosome brucei gambiense. These are briefly 
discussed below: 
a) Falcipains-2 and 3 are the major cysteine proteases of the protozoan parasite P. Jalciparum 
and expressed by the erythrocyte trophozoites. IntraerythroCyiic trophozoites derive amino acids 
for protein synthesis from degradation of host cell hemoglobin in the acidic food vacuole. [46.55] 
Proteases that hydrolyze hemoglobin include members of aspartic proteases (plasmepsin I and 
II), cysteine proteases (jalcipains 2 and 3) and Jalcilysin families. Falcipain-2 and Jalcipain-3 
appear to be the principal cysteine proteases in this degradation. The most active between the 
two is Jalcipain-2, however, both have similar specificities of strong preference for the leucine 
amino acid residue. The role of Jalcipain-l is not clear, but presumed to be active during 
invasion of erythrocytes. [56] 
Compounds that inhibit Jalcipain-2 or 3 block hemoglobin degradation and prevent parasite 
development. For example, cha1cones and peptidic vinyl sulfones have been shown to cure 
malaria-infected mice.[46] Correlation between Jalcipain-2 or 3 inhibition and parasite 
development was found, supporting the hypothesis that Jalcipain is the cysteine protease 
required for hemoglobin degradation. 
b) Cruzain (also known as Cruzipain) is the maJor cysteine protease in the parasite 
Trypanosoma cruzi, the causative agent for American Trypanosomiasis. This enzyme so much 
related to cathepsin L, plays an essential role in the life cycle of the parasite such as replication 
and transformation between stages of T. cruzl. [57] 
c) Rhodesain is a cysteine protease found in Trypanosoma brucei rhodesiense a major agent in 
Human African Trypanomiasis. [58] The enzyme has also been identified to be vital in the life 
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2.1.4 Postulated Catalytic Mechanism of Cysteine Proteases 
The success in development of new potent cysteine protease inhibitors depends on a better 
understanding of the enzyme's mechanism. Below is a proposed mechanism similar among all 
cysteine proteases and involves utilization of an active cysteine thiol (as a catalytic nuc1eophile) 
for peptide bond cleavage. [59] Histidine and asparagine residues are in close proximity and assist 




Scheme 1. Proposed catalytic mechanism for cysteine proteases. 
The imidazole group of the histidine polarizes the SH group of the cysteine and enables 
deprotonation. The thiolate, which is highly nucleophilic, attacks the carbonyl carbon of the 
peptide bond to be cleaved (i) and leads to the fonnation of a tetrahedral intermediate (ii). 
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The tetrahedral intermediate now breaks down by the departure of protonated amino group (iii). 
Re-protonation of histidine (iv) helps to generate a base that attacks the carbonyl carbon of the 
ester. The tetrahedral adduct collapses (v) with the release of a carboxylic end of the peptide 
followed by protonation of the thiolate anion (vi). 
2.2 Mechanistically Distinct Classes of Inhibitors of Cysteine Proteases 
2.2.1 Introduction 
Naturally, cysteine proteases are inhibited by cystains and serpins. Cystatins are reversible 
inhibitors of cysteine proteases and are widely distributed in the human body, while serpins are 
covalent inhibitors of proteases and exhibit diverse roles, including regulation of blood clotting, 
fibrin cleavage, and inhibition of apoptosis. 
More recently, the development of cysteine protease inhibitors has drastically increased 
probably driven by advances in knowledge, computer-aided design and use of combinatorial 
syntheses. The striking features of all cysteine protease inhibitors are; (i) electrophilic head 
group and (ii) a substrate binding group(s). The most recent cysteine proteases inhibitors 
reported include reversible, irreversible and slow-turnover inhibitors. [60] 
i). Reversible inhibitors 
Reversible inhibitors usually involve non-covalent or covalent yet reversible interaction 
between the active site of the enzyme and the inhibitor. They form weak bonds and do not 
permanently disable the enzyme. Bonds in the enzyme-inhibitor complex form easily and are 
easy to break. Methylisatin-5-carboxamide 14 [61], isatin sulfonamide 15 [621, cyclic ketone 16 [631 













HRV -3C protease: Ki = 51 nM 
17 
HRV -3C protease: Ki = 51 nM 
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caspases-3 and -7: K, 1.2 nM 
Figure 5. Reversible inhibitors of cysteine proteases. 
ii) Irreversible inhibitors 
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cathepsin K: K, app = 140 n M 
cruzain: IC50 = 0.8 - 2.9 11M 
rhodesain: ICs() = 2.5 11M 
cathepsin B: IC50 =10 11M 
Irreversible inhibitors act by fonning strong bond with the cysteine protease active site whilst 
the inhibitor inactivating its catalytic activities. They generally stay in the active site for a long 
time and permanently disable the enzyme. These inhibitors are associated with toxicity e.g 
vinyl sulfone 19 (fig. 6) is an irreversible inhibitor of cysteine proteases. [66] 
cruzipain: kc/K, 6.5 x 10 6 M·1s·! 
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iii) Slow-turnover Inhibitors 
Slow-turnover inhibitors on the other hand, are a senes of compounds that form a stable 
thioacyl-enzyme complex with the active site of the cysteine protease and is very slow to 
hydrolyze. The best example of this series of inhibitors is the diacyl hydrazine derivative 20 
(fig. 7). [67] 
o H s~ 
CBzHN II N. 1::-. \ ... H ... CBz ~N' ]N
= H 0 
20 
cathepsin K: K, = 10 nM 
cathepsin B: K; = 5200 nM 
cathepsin L: K; 700 nM 
cathepsin S: K, = 1000 nM 
Figure 7. Slow-turnover inhibitor of cysteine protease. 
2.3 ISATIN AND ITS CHEMISTRY 
2.3.1 Introduction and Occurrences 
Isatin 21 (fig. 8), systematically known as indole-2, 3-dione, is a natural product found 
predominantly in plants of the genus Lmtis. [68] It is a bright-orange crystalline solid with an 
unpleasant odour. Its nucleus is basically a nitrogen-containing heterocyclic (pyrrole) fused to a 
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Figure 8. Isatin (Indole-2, 3-dione) 
Isatin and some of its derivatives are available commercially and all these are produced 
synthetically; for example, isatin is made by reacting aniline, chloral hydrate and hydroxylamine 
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Historically, Erdman and Laurent discovered isatin in 1841 as a substance obtained from the 




22 23 24 
Figure 9. Naturally occurring derivatives of isatin. 
Isatin is probably the most versatile and widely distributed heterocyclic compound in nature. 
For example, in plants isatin is found as a melosatin alkaloid (methoxy phenylpentyl isatin) 22 
(fig. 9), [71,72] in fungi as 5-(3-methylbuten-2-yl) isatin 23 (fig. 9) and 6-(3-methylbuten-2-yl) 
isatin 24 (fig. 9), both were isolated from streptomyces albus [73] and chaetomium globosum, [74] 
respectively. 
In animals, it is found as a component of the secretion from parotid glands of a bufo frog, also 
produced by an alteromonas sp., which protects embryos of the shrimp palaemon 
macrodaetylus from the pathogenic fungus lagenidium callinectes; whilst in humans as a 
metabolic derivative of adrenaline and as a component of tribulin in human tissue and body 
fluid. [75] Isatin has also been found to be a component of coal tar. [76] 
2.3.2 A Review of Isatin Chemistry 
2.3.2.1 Synthesis of isatin 
A variety of work on synthesis of isatin is well documented since its isolation in 1988. [69] 
Mostly, the strategy used depends on the availability of reagents, the number of synthetic steps 
and chemical yields. 
a) The Sandmeyer Approach 
The commonest and oldest approach is the Sandmeyer synthesis. It involves reacting aniline 
with chloral hydrate and hydroxylamine hydrochloride in aqueous sodium sulfate to initially 
form an intermediate isonitroacetanilide 26. Cyclization of 26 with concentrated sulfuric acid 






















Scheme 2. Synthesis of isatin by Sandmeyer approach. 
b) An Alternative Method for the Synthesis of Isatin 
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21 
Another approach is based on a regiospecific conversion of aniline to isatin. This method makes 
use of the reaction of an o-lithiated and protected aniline derivative 27 with diethyl oxalate to 
give an a-ketoester 28 which upon deprotection, readily undergoes cyclization to afford isatin in 
good yield, (Scheme 3). [78] 
crNHCOR I 1. BuLi, THF '/~ ... 
X 2. (C02Eth 
27 28 
Scheme 3. Synthesis of isatin via regiospecific conversion of aniline. 









Isatin and its derivatives have been widely investigated for use as building blocks in synthesis of 
heterocyclic compounds, natural products, and potentially important pharmaceutical agents. 
Isatins, for example, may react with nucleophiles, electrophiles and other reagents to give 
various products. [69] 
2.3.3.1 Reactions with Bases 
As in pyrrole, the N-hydrogen in isatin is acidic and can be deprotonated by a base such as 
sodium hydride to form sodium isatide 29 (fig. 10), often represented as resonance-stabilized 
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Figure] O. Resonance structures of isatin anion. 
Since the carbonyl group (C-2) is similar to that of normal amides, sodium isatide often 
hydrolysizes when heated in basic solutions. Hydrolysis of this heterocyclic ring of isatin forms 
o-aminophenylglyoxylic acid 32, which can be useful in the synthesis of quinoline derivative 33 
in the presence of chloroacetone, (fig. 11). This ring opening reaction of isatin has been shown 
to be a very convenient method for the preparation six-membered quinoline heterocyclic 
systems. 
o 








Figure It. Hydrolysis and six-membered ring products of isatin. 
2.3.3.2 Reactions with Oxidizing and Reducing Agents 
Oxidation of isatin with chromic acid or hydrogen peroxide leads to ring expansion giving the 
corresponding isatoic anhydride 34, isatoic anhydride is also useful in the synthesis of 
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On the other hand, reduction of isatins can lead to either 1 or 3 alkylated indole products 
depending on the nature of reducing reagent being used. Lithium aluminum hydride and alkyl 
lithium has been applied to synthesize 3-alkylindoles, whilst sodium hydride, alkyl halide and 
sodium borohydride in THF reduces isatins to l-alkylindoles, respectively. [79] 
2.3.3.3 Electrophilic Substitution Reactions 
Electrophilic substitution of isatins occurs predominantly at positions 5 andlor 7 of the aryl 
system due to the electronic effect of the nitrogen. The electron-donating nature of the hetero-
nitrogen usually directs in coming electrophiles arrha and lor para positions depending on the 
solvent. Typical electrophilic reactions such as halogenation, nitration and sulfonation follow 
the same pattern. For example, bromination of isatin with N-bromoacetamide in acetic acid to 
afford 5-bromoisatin is reported and was achieved in high yield, (Scheme 5a). [801 
o 
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Scheme 5. (a) N-bromoacetamide, CH300H, 90 %; (b). Br" 95 % warm EtOH, 80 %. 
Similarily, Lindwall and co-workers have shown the synthesis of 5, 7-dibromoisatin using 
bromine in the presence of warm 95 % ethanol to afford the 5, 7-dibromoisatin 37 in 80 % yield, 
(Scheme 5 b). 181] 
2.3.3.4 N-substituted Derivatives 
Isatin and its derivatives react with alkyl, acyl and sulfonyl halides to give N-alkylisatin, N-
acylisatin and N-sulfonylisatin, respectively. For example, N-alkylated isatin can be obtained 
simply by reacting isatin with alkyl electrophiles in the presence of a base under mild reaction 
conditions. Amongst the most convenient reactions reported is the use of sodium hydride as 
base. However, Shuttleworth and co-workers used substituted isatins 38 in the synthesis of N-
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diethylamino-l, 3-dimethylperhydro-l, 3, 2-diazaphosphorine on polystyrene (BEMP) as a base 
in acetonitrile to give derivatives in high yield >90 %, (Scheme 6). [82] 
38 
Scheme 6. (a) 1.05 equiv. ofBEMP, 1.05 equiv. of a-bromo ketone, MeCN, 45°C, 16h. 
2.3.3.5 Reactions with Nucleophiles 
As with ordinary ketones, isatins undergo nucleophilic addition reactions at the ketonic C-3 
carbonyl group. Nevertheless, those involving addition at amide C-2 carbonyl have been 
reported, too. [69] Often the chemoselectivity of these reactions is highly dependent on the nature 
of nucleophile, solvent and temperature. For instance, a-phenylenediamine reacts with isatin and 

























Scheme 8. (d) methanol. rt, 48 h. 67%. 
As depicted in Scheme 7, acidic solvents such as acetic acid led to the production of a 2, 3-
condensation product 40, while a switch to N-methyl-2-pyn'0Iidine afforded a spiro compound 
41 in high yield. On the other hand, a ring-opened quinoxalinone 42 was obtained as the major 












In a similar experiment, usmg a different nucleophile (2-aminobenzylamine) formed sole 
product 44 and none of 2, 3-condensation products were observed despite varying the solvents, 
(Scheme 8). 
2.4 Other Reactions of Isatins 
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Since isatins possess a reactive keto-carbonyl (C 3) group, they readily undergo reactions with 
activated vinyl compounds 45 under mild conditions to afford Baylis-Hillman related products 
46. Chung and co-workers previously reported using THF and DMF to afford desired products 











2.4.2 Schiff and Mannich bases of Isatin and its Derivatives 








Scheme 10. (i) EtOH, CH300H, 72 %. (ii). CH20, THF, 91 %. 




Mannich reactions have been applied to isatins. Numerous reactions gIvmg N-
aminomethylisatin products have been previously reported starting with pyrimidine 47 and 
intermediate imines 48. Pandeya and co-workers successfully synthesized a series of pyrimidine 
Mannich bases 49 in good yield by the condensation of the acidic amino group of the isatin with 











Background and Rationale 










Scheme 11. (i) EtOH; (ii) THF, CH20. 
Another interesting series of Schiff and Mannich bases of isatin reported by Pandeya et at were 
synthesized from thiosemicarbazide and thiosemicarbazone 50 and 51, respectively to give (p-
chlorophenyl) thiazol-2-yl thiosemicarbazones 52, (Scheme 11). [86] All were achieved using a 
similar protocol as described above and afforded the desired product in good yield. 
2.5 BIOLOGICAL PROPERTIES OF ISA TIN AND ITS DERIVATIVES 
Isatins are very active in many biological processes. Their biological activity on several 
important components in both plants and animals are so drastic that they affect the systems in 
which they are found. For example, it has been found to affect a variety of enzymes, sometimes 
tissues and receptors. The most notable effects documented are listed below. 
i). In 1995, lyer and co-workers reported that simple N-BOC and N-CBZ-isatin analogues 53 
acted as reversible, slow-binding inhibitors of serine proteases, and exhibited selectivity 











ii) Caspases-3 and 7 are intracellular cysteine proteases involved in apoptosis (programmed 
cell death). A series of isatin sulfonamide inhibitors have been reported and these have 
selectivity within the caspase family. As mentioned before, Lee and co-workers have 
reported isatin sulfonamide 15 as an irreversible inhibitor for caspases 3 and 7 cysteine 
proteases with inhibitory constant Ki = 1.2 nM and 6.0 nM, respectively. [62J 
iii). Recently, Webber and co-workers investigated a series of N-aklyl-5-isatin carboxamide 
derivatives 14, 54, 55 and 56 (fig. 12) as inhibitors of human rhinovirus (HRV) protease. 
HRVs etiologic agents of the common cold are cysteine protease with a trypsin-like 
polypeptide structure. [61] 
o 
14 54 55 
56 
Figure 12. Inhibitors of Human Rhinovirus (HRV) Protease. 
iv). Isatin has been shown to inhibit monoamine oxidase MAO in humans. MAO is an enzyme 
that metabolizes a wide range of mono-amines and is important in the control of the 
concentration of these neurotransmitters. Several studies have associated stress, anxiety 
and depression to MAO. [88J 
v). Sehiff and N-Mannich base derivatives of isatin are reported to possess a variety of 
properties that include; anticonvulsant [89), anti-flammatory [90J, antibacterial [91 1, antifungal 
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vi). Isatin also inhibits acetyl cholinesterase (AchE) in the brain and blood. AChE is known to 
act very rapidly to stop neurotransmission at cholinergic synapses found in the brain and at 
neuromuscular joints. Inhibition of AchE is important in medicine as a target for drugs for 
the treatment of Alzheimer's and related diseases. [97] 
2.6 RATIONALE FOR CHOICE OF THE ISATIN SCAFFOLD FOR ANTIPARASITIC 
CYSTEINE PROTEASE INHIBITORS DESIGN 
Various derivatives of isatin are known to possess a range of pharmacological properties 
including antiprotozoal activities [94] as earlier mentioned. Within the context of enzyme 
inhibitors, isatins have seen recent applications in the inhibition of cysteine and serine proteases. 
[g7l Thus isatin is a biologically validated starting point for the design and synthesis of chemical 
libraries directed at these targets. Due to the privileged nature of isatin, libraries designed and 
synthesized around the basic structure of this scaffold should yield medicinally active 
compounds with high hit rates at significantly reduced library size compared to large classical 
libraries obtained from combinatorial chemistry efforts based on non-privileged templates. 
The aforementioned anti protozoal and cysteine protease inhibitory activities of isatin derivatives 
prompted us to investigate this class of compounds as potential ketone inhibitors of parasitic 
cysteine proteases identified in trypanosomes (cruzain and rhodesain) and malaria parasites 
(ja/cipain-2), respectively. [98-101] It is noteworthy that a series of highly potent reversible ketone 
inhibitors of cruzain have previously been disclosedJ102 l This has recently culminated in the 
first crystal structures of these inhibitors being solved. [103] We reasoned that the presence of the 
ketone functionality adjacent to the aromatic ring on the isatin scaffold provides a diversity 
point for accessing the corresponding thiosemicarbazones, a class of compounds recently 
identified as potent antitrypanosomal inhibitors of cruzain.[104] Coupled with the molecular 
simplicity, potentially cost effective synthesis and non-peptidic nature, this makes isatins 
attractive scaffolds for antiparasitic drug discovery. Cost-effective synthesis should always be a 
consideration in deciding on potential new antiparasitic agents given the prevalence of major 
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2.7 PROJECT AIMS 
i). To utilize KF/Ah03 as a convenient supported base in the synthesis of target isatin and 5 
and/or 7 lV-substituted isatin derivatives. 
ii). To synthesize isatin-3-thiosemicarbazone derivatives. 
iii). To synthesize quinoline and non-quinoline Mannich base isatin derivatives. 
iv). To synthesize quinoline-ethylene isatin derivatives for comparison with corresponding 
Mannich bases. 
v). In collaboration with appropriate laboratories, to conduct the biological evaluation of 
commercially available and synthesized compounds against the three cysteine protease 
enzymes (falcipain-2, cruzain and rhodesain) and cultured malaria parasites in vitro. 
vi). To explore structure-activity relationships within each series of compounds in an effort to 
identify the most promising commercially available and synthesized scaffold for further 
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CHAPTER 3 
ISATIN DERIVATIVES: SYNTHESIS AND CHARACTERIZATION 
3.1 N-SUBSTITUTED ISATIN DERIVATIVES 
3.1.1 Background and Rationale 
A number of biologically active compounds contain aromatic ring systems as part of their 
structures. Aromatic ring systems are reported to have an excellent binding affinity for proteins. 
Structure-activity relationship studies have shown that an aromatic moiety is involved in weak, 
non-covalent 1Ht interactions with non-polar sites of proteins and also bind to polar substituents 
such as amides and hydroxyl groups through cation-1/: interactions. [l05. 106) Thus, incorporating 
aromatic moieties in a drug is vital for enhancing molecular recognition and protein-drug 
interactions, and hence the desired biological activity. These considerations led us to design an 
initial exploratory series of potential antiparasitic cysteine protease inhibitors 57a-57i (N-benzyl 
derivatives), 58a-58b (N-acyl and sulfonyl derivatives) and 59a-59d (carboxybenzyl 
derivatives) based on the isatin scaffold. 
In arriving at exploratory compounds 57a - 59d, we considered the isatin nucleus as a central 
scaffold to which suitable substituents could be rationally appended. Previous work on 
inhibitors of other cysteine proteases pointed to the importance of an N-benzyl substituent in 
compound 57 for effective inhibition. [107] This substituent was thought to bind in the S2 pocket 
of the enzyme. Proteases bind peptide substrates in their active site cleft through backbone and 
side chain interactions that lie around several defined pockets in the enzyme termed Sl, S2, S3, 
S4 for those that bind to the corresponding amino acids that are N-terminal to the scissile amide 
bond while the S 1', S2', S3', S4' pockets bind to the amino acids C-terminal to the scissile bond. 
Since the isatin scaffold had previously not been used for parasitic cysteine protease inhibitor 
design, we considered the aforementioned previous work on umelated cysteine protease as a 
useful starting point In addition to the more flexible N-benzyl system in 57, we wished to 
explore the potential of more rigid N-acyl and N-sulfonyl derivatives 58a-58b in which rotation 
about the N-C (amide/sulfonamide) bond is relatively speaking somewhat restricted compared 
to 57a-57i. Furthermore we reasoned that the carbonyl oxygen in derivatives 58a-58b and 59a-
59d could be involved in other (hydrogen bonding) interactions with suitable sites within the 
protein. The rationale behind derivative 59a-59d is that a member of this series, N-
(carbobenzyloxy) isatin, has been investigated as a slow or weak inhibitor of chymotrypsin 
(chymotrypsin is a serine protease which catalyses the hydrolysis of peptide bonds preferably 
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The initial goal was to carry out a limited comparative study of representative compounds from 
57a-59d with respect to inhibition of three parasitic cysteine proteases, cruzain, falcipain (2 or 
3), and rhodesain. It was envisaged that preliminary biological data on representative 
compounds would be used as a basis to launch a more focused future medicinal chemistry 
programme around the most promising series. Although various substituted isatins can be 
synthesized, [69] we initially concentrated on the use of commercially available isatins. 
57a-57i 58a-58b: X = C, SO 59a-59d 
3.1.2 Synthesis and Characterization 
3.1.2.1 Synthesis of derivatives 57a-57i and 58a-58b 
Compounds in the series 57a-57i and 58a-58b were prepared as depicted in Scheme 12. For the 
synthesis of compounds 57a -57i, a series of commercially available isatins (l.0 equiv) were 
treated with benzyl halides (1.2 equiv) in CH2Ch as solvent in the presence of 4.0 equivalents of 
potassium fluoride on alumina (KF / Ah03). The reaction mixtures were stirred at room 
temperature for 16 hours, after which the resultant mixtures were simply diluted with diethyl 
ether and the crude isolated. Purification of the crude reaction mixtures by column 
chromatography over silica gel (3:7; EtOAc: Hex) generally gave high yields of the desired 
products (Table 1). During our method development, we observed that 4 equivalents of the base 
were necessary to drive reactions to completion and that prior to purification by column 
chromatography, the reactions had proceeded cleanly with only the excess benzyl halide present 
in addition to the product. 
a .. 
38 57a-58b 
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KF / Ah03 was preferred to other bases like sodiwn hydride (NaH) due to ease and convenience 
of reaction work-up and product isolation, which made it suitable in parallel synthesis. This 
immobilized reagent has been used by numerous researchers in similar contexts as ours. 
Potassium fluoride on alumina was first used for the functionalization of amides in 1981 by 
Yamawaki [109'] but has now recently been utilized in a variety of synthetic transformations 
including arylation, esterification, alkylation, heterocycle-formation and other important solid 
phase syntheses. [I09J To lay some emphasis on the appreciable work done by employing 
KFIAh0 3; 
i). Diaryl ether derivatives previously that could not be formed by the characteristic Ullman-
coupling reactions (due to electronically unfavorable substituents) can now be accomplished by 
using KFI Ah03 at elevated temperatures. [IIOJ 
ii). KF I Ah03 has been demonstrated to enhance selectively N-alkylation of 2-oxazolidinone 
and carboxylic acid methyl ester 60 and 61 respectively, completely suppressing the competing 
O-alkylation. In a similar context, mono-functionalization of benzodiazepin-2, 5-diones 62 was 
accomplished using acetonitrile or dimethoxyethane in the presence of KFI Aha. [I I I-I 13] 
60 61 62 
iii). Investigations into the possible utilization of KF I Ah03 in palladium-catalyzed cross-
coupling reaction has demonstrated that the base is effective over a wide range of both aryl 
bromides/iodines and boronic acids. However, vinyl halides did not favour KF I Ah03 as base. 
1114] 
iv). Deprotection of silyl ethers typically requiring various conditions such use of TF A, formic 
acid and fluoride reagents, can be achieved by using KF I Ah03 in a solvent dependent manner. 
Interestingly, various silyl protecting groups (TMS, TBDMS and TBDPS) can now be 
effectively, selectively and cleanly removed. [115] 
In our work, the use of KF / Ah03 was also extended to the parallel synthesis N-acyl and N-
sulfonyl isatin derivatives. Reaction of isatin with benzoyl or sulfonyl chloride in CH2Ch in the 
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yield respectively. Although the yields are unoptimised, the reactions proceeded without any 
complications. Overall results are presented in Table 1. 
The reaction of isatin with benzoyl chloride is particularly noteworthy. The synthesis of N-
acylisatin derivatives under various conditions have been described, for instance using 
triethylamine in benzene, pyridine in benzene or triethylamine in chloroform. However, these 
reactions are associated with a number of drawbacks such as formation of complex products. [69J 
Table 1. N-alkylated, N-acylated and N-sulfonylated isatin derivatives prepared by parallel synthesis using 
KF/AI 20 3· 
Compound Time (hrs) %Yield 
57a H H 16 95 
57b I H 16 65 
57c Me H 16 54 
57d Me H 16 76 
57e Me H 16 60 
57f Me H 16 72 
57g CI H 16 63 
57h CI H 16 70 
57i CI H 16 70 
58a H H 24 84 
58b H H 20 48 
The synthesized compounds were confirmed from their high-resolution mass spectra and 
spectroscopic data together with their elemental analyses. The infrared spectra in solid state 
using KBr for the products showed the absence of a broad N-H peak (3400-3150cm- 1) 











The lH NMR spectra for the benzyl series of compounds 57a - 57i show essentially two sets of 
signals for aromatic and methylene protons. This is exemplified in Figure 13 below, which is the 
proton NMR spectrum of compound 57a. The methylene (H-8) protons in the molecule are 
characteristic of the compound and were observed as a singlet at 0 4.93 ppm, integrating for two 
protons. The appearance of a multiplet in aromatic region at 0 7.30 ppm, integrating to five 
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Figure 13. lH NMR spectrum of compound 57a in CDCh 
In the aromatic region, H-4 which appears at 0 7.61 ppm as a double doublet (dd) is the most 
deshielded. This is due to the neighboring electron withdrawing dicarbonyl effect. On expansion 
of NMR spectrum of 57a, H-4, 11-5, and H-6 were clearly a double doublet, double double 
doublet and double double doublet, respectively. The expected double doublet for H-7 was not 
evident even on expansion and the multiplicity observed was a broadened doublet at 0 6.79 
ppm. The doublet actually observed for H-7 is probably due to low resolution and lor splitting of 
H-7 at the NMR field (300 MHz) used. There may be something unusual about the magnetic 
environment for H-7 in this and related isatins. Since 57a is a known compound, a literature 
search revealed the same observation of H-7 as a doublet by other authors. [116] Nevertheless, 
more evidence for compound 57a was given by disappearance of N-H signal in the lH NMR 
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No significant variation in the chemical shift values with change in substituents was observed 
across the series of compounds 57 for the common hydrogen and carbon atoms. The l3C NMR 
spectra of the compounds showed c=o signals at 8 183.0 ppm (C-3) and 8 158.2 ppm (C-2). An 
additional c=o peak at 8 166.7 ppm was observed for the exocyclic c=o of 58a. 
The high-resolution mass spectrometry (HRMS) was used to confirm the molecular masses of 
the compounds and in each case found to be very close to the calculated values. Furthermore, 
attempts to study the fragmentation pattern was made and it was found that the peak 
corresponding to mlz 91.0 (C6H4N)+ was observed in compound 57a. This peak was attributed 
to the six-membered ring fragment (arene aziridine) and this might arise from the loss of the two 
carbonyl groups and the N-substituent. 
3.1.2.2 Synthesis of Isatin Chloroformate Derivatives 59a-59d 
In view of the previously mentioned (apparent) potential of N- (carbobenzyloxy) isatin as a 
biologically active molecule, we set out to make a preliminary array of 5-isatin substituted 
derivatives. The synthesis of derivative 59a has been previously reported by Ramaswamy A et 
al and was prepared following the literature procedure in 76% yield. [\07] For other analogs 59b-
59d, the same procedure was used. Accordingly, isatin / 5-substituted isatins 63 (1.0 equiv) was 
dissolved and stirred in CH3CN at 0 °c in an ice bath. Benzyl chloroformate (1.1 equiv) was 
then added slowly followed by 0.1 equiv. of 4-dimethylaminopyridine (DMAP) and 
triethylamine (1.1 equiv). After stirring for 3 hours at 0 °c the desired products were obtained 
by filtration from the reaction mixture, washed with cold ethanol, dried and recrystallized from 
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Table 2. N- (carbobenzyloxy) isatin derivatives synthesized and their percentage yields. 
Compound R % Yield mp (lC) 
59a H 97 152 - 154 
59b CI 19 166 
59c Me 24 144-150 
59d F 35 >350 
3.1.2.2 Mechanism 
The supposed reaction mechanism of acylation of isatin, in which DMAP acts as an acyl 
transfer catalyst, is schematically represented in Scheme 14 below. Nucleophilic attack of 
DMAP on the carbonyl group of benzyl chloroformate results in a more reactive intermediate 
which is rapidly attacked by the nucleophilic deprotonated isatin to give the final product 59. 
Regeneration of DMAP accompanies product formation along with triethylammonium 
hydrochloride. 
Et3N.HCl + DMAP 
R~O 
II :I )=0 
~N 
+ 
DMAP + Et3N.HCl 











Results and Discussion 
The key spectroscopic indicators in the IH NMR spectrum of the compounds includes the 
presence of additional aromatic protons between 8 8.15-7.32 ppm, a singlet for the benzylic (11:-
9) protons around 8 5.48 ppm. Pertinent data is summarized in Table 6. 
Table 3. I H NMR Chemical shifts of N-chloroformate isatin derivatives 
o 
o 




Compound H-4 H-5 H-6 H-7 -OCH2Ar Ph 
59a 7.78 7.32 7.74 8.15 5.48 7.54-7.35 
59b 7.72 ~ 7.68 8.13 5.47 7.49-7.38 
59c 7.55 ~ 7.54 8.01 5.46 7.42-7.35 
59d 7.50 ~ 7.54 8.18 5.36 7.39-7.32 
3.2 ISATIN-3-THIOSEMICARBAZONES 
3.2.1 Background and Rationale 
Within the context of cysteine protease inhibitors, the rationale for pursuing thiosemicarbazone 
derivatives of isatin is at least five-fold. 
i) First, the corresponding semicarbazones, as a class, are known general cysteine protease 
inhibitor scaffolds. Peptidyl semicarbazones have been shown to be inhibitors of cysteine 
proteases (albeit weaker than the corresponding aldehydes). Inhibition of cysteine proteases by 
peptidyl semicarbazones is due to the formation of a tetrahedral adduct by attack of the active 
site thiolate on the imine carbon of the semicarbazone, [117) (Scheme 15). 
R R/i ____ " R>_ r(R1 1 
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Results and Discussion 
A histidine group which is in close proximity polarizes the enzyme-cysteine thiol group 
allowing deprotonation even under neutral to weakly acidic pH conditions. The resulting 
nucleophilic thiolate/imidazolium ion pair allows the thiolate anion attack the imine as 
mentioned before. 
II) Second, non-peptidic thiosemicarbazones have been recently identified as potent anti-





Scheme 16: Inhibition of cysteine protease by thiosemicarbazones. 
~ /~ S-Cys25 
Ar N 1--NH2 
SH 
His 159-lm 
The mechanism of inhibition of cruzain by thiosemicarbazones has been proposed via attack of 
the enzyme-thiolate anion on the thiol carbonyl resulting in formation of tetrahedral adduct. The 
attack is driven by the assisted protonation of thiosemicarbazone sulfur by His 159, (Scheme 
16). Experimental and computer modeling results supports this mechanism. [104) 
iii) Third, irrespective of the mechanism of inhibition described in (i) and (ii) above, the 
reactions are reversible. This has implications for (low) host toxicity and purification of target 
cysteine proteases by affinity chromatography. 
iv). Compared to 3-imine derivatives, (thio) semicarbazone derivatives of isatin are more 
stable and less prone to hydrolysis. This has implications for bioavailability in vivo. The 
presumed stability of (thio) semicarbazone derivatives (X = 0, S) relative to simple imines is 
based on stabilization of the imine double bond by the electronegative nitrogen substituent. This 
makes the imine double bond (C=N) of (thio) semicarbazones less prone to nucleophilic attack 
compared to simple imines, (Scheme 17). 











Results and Discussion 
v). Like biguanides, thiosemicarbazones are metal chelators (via the sulfur and hydrazinic 
nitrogen atoms) which may act as metal-interactive inhibitors of cysteine proteases. [118] 
Initially we aimed to only study commercially available isatins with respect to substituents Rl, 
R2 and R3 (Scheme 18). The ultimate aim is to identify the most promising commercially 
available isatin scaffold on which to base inhibitor design and synthesis. Coupled with previous 
studies on N-substituted isatins described before, it was envisaged that this would lead to 
preliminary structure-activity relationship (cysteine protease inhibitor) data to be generated and 
used in further future rounds of design and synthesis. 
3.2.2 Synthesis and Characterization 
3.2.2.1 Synthesis 
The synthesis of thiosemicarbazones 64a - 64k was carried out according to a literature 
procedure by straightforward condensation of a number of commercially available isatins with 
thiosemicarbazide. In each case, equimolar quantities of isatin and thiosemicarbazide were 
initially dissolved in 10 mL of warm 95% ethanol and heated with continuous stirring at 45°C 
for 3-6 hours. The resultant mixtures were cooled to room temperature and allowed to stand for 
24 hours. Crystalline products 64a-64k were formed which were filtered, washed with ethanol, 
dried and recrystallized (from ethanol). The overall yields were in the range 39-98%. The yields 
were dependant on the rate of crystallization of each individual compound from solution. The 
low yield of 64a may be due the fact that part of the product had remained in the mother liquor. 
Scheme 18 below depicts the synthesis of isatin-3-thiosemicarbazone and its derivatives. The 
overall results are presented in Table 4. 
21 64a-64k 











Results and Discussion 
Table 4. Isolated yields and data for synthesized isatin-3-thiosemicarbazones 
Compound Rl R2 R3 Time (Hours) % Yield mp (oC) 
64a H H H 4 43 249-253 
64b F H H 4 82 287-289 
64c Cl H H 4 73 283-285 
64d Br H H 4 43 281-284 
64e I H H 4 67 265 
64f Cl Me H 4 98 >350 
64g Me H H 4 74 281-283 
64h Me Me H 4 90 286-287 
64i N02 H H 4 88 >350 
64j H H Ph 6 76 245-249 
64k H H Me 6 97 253 
3.2.2.1 Mechanism 
A possible mechanism for the formation of compounds 64a-64k is presented in Scheme 19 
below. Nucleophilic addition of the more nucleophilic terminal amino group to the ketone 
carbonyl of the isatin results in an intermediate from which proton transfer from the nitrogen to 
the negatively charged oxygen follows to give a neutral molecule. Subsequently, elimination of 
water gives the required products 64. Nucleophilic attack occurs preferentially at the ketone 
carbonyl group (C-3) since this carbonyl group is more electrophilic than the amide carbonyl. 
However, it is noteworthy that the reaction of I-aryl or l-arylsulfonylisatin with hydrazine or 
thiosemicarbazine is reported to (sometimes) lead to products of nucleophilic attack at amide 











Results and Discussion 
work, only one (predominant) C-3 product is obtained. It may be assumed that solvents playa 
role in reactions too. 
Scheme 19. Mechanism for the formation of isatin-3-thiosemicarbazones. 
The synthesized compounds 64a-64k were fully characterized by IR, IH NMR, I3C NMR, mass 
spectra as well as elemental analysis. The infrared spectra of showed characteristic peaks in 
respect of four major functional groups, secondary N-H (3414 em-I), amide C=O (1684 em-I), 
C=N (1699 em-I) and C=S (1137 em-I). The absence of a ketone (C=O) band at 1730 cm- l 
provided further proof of product formation. The lH NMR spectrum (DMSO-d6) for compound 
64a is shown (Figure ] 4). Key signals in the spectra of all the compounds are three sets of 
chemical shifts at (5 12.46 ppm (NNH), (5 11.15 ppm (H-l) and (5 8.98-8.62 ppm (NHH and 
NHH). Aromatic ring protons appear in the region (57.65 - 6.92 ppm, where a double doublet is 
observed at (5 7.64 ppm for H-4 with J 1.2 and 7.5 Hz, a double double doublet at (5 7.34 ppm 
with J 1.2,6.9 and 7.6 Hz for H-6, another double double doublet at (5 7.09 ppm with J 0.9, 
6.9 and 7.5 Hz for H-5 and a doublet at (56.92 ppm attributed to H-7. The expansion (not shown 
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Figure 14. lH NMR spectrum of compound 64a in DMSO-d6. 
The IH NMR for the 5 and 7-substituted isatin derivatives are similar to 64a with no significant 
changes in chemical shift values for common protons. The stereochemistry (E, Z) of isatin-3-
thiosemicarbazone about the double bond was not investigated. However, from the NMR 
spectra, one predominant isomer was obtained. The possibility of intra-molecular H-bonding 
involving the thiosemicarbazone NH and the C-2 carbonyl oxygen would favour the Z isomer as 
shown for 64a in Figure 14. This intra-molecular H-bonding partly accounts for the deshielding 
of the NNH proton which appears at 12.5 ppm. The l3C NMR spectra revealed further evidence 
on the structures of the products. For instance, the spectrum of compound 64a, shows the C=S 
carbon at 8 178.7 ppm, resonance for the amide carbonyl (C-2) at 8 162.6 ppm, the C=N at 8 
142.3 ppm and disappearance of the ketonic carbonyl (C-3) peak at 183.2 ppm in the starting 
material. The aromatic carbons appear in the region 8 131.9-110.9 ppm. 
Further support for the structures was provided by the mass spectra, which indicated the (found) 
molecular ion close to the calculated masses. For example, the molecular ion observed for 
compound 64a was mlz 220.04245. A fragmentation pattern was observed for the molecule, 











Resu Its and Discussion 
[C3HSN4S],+ mlz 132.04598 (30%) and [C7H6N],+ mlz 104.0507 (35%). A similar fragmentation 
pattern was observed in the other derivatives. 
3.3 QUI~OLI~E N-MANNICH ISA TIN DERIVATIVES 
3.3.1 Background and Rationale 
Quinolines are naturally occurring heteroaromatic molecular structures found in coal tar and 
other products of fossil fuel. [120] Quinoline and its derivatives have interesting chemistry and 
have been used widely in the treatment malaria for more than 350 years. Quinine was the first 
quinoline antimalarial natural produet which led to the discovery of synthetic derivatives such 
as chloroquine, mefloquine, and amodiaquine to mention a few. It is postulated that quinoline 
antimalarials accumulate in the parasite's acidic food vacuole and inhibit ~-haematin formation. 
Toxic heme thus builds up in the vacuole subsequently killing the parasites. [121. 122] Though the 
actual mode of action of these agents is still unclear, they still remain potential sources of 
today's and future antimalarial therapy. This is partly because Plasmodium jalciparum has had 
difficulty developing rapid resistance to this class of compounds. For example simple 
modification of the lateral side chain of chloroquine has resulted in derivatives with activity 
against chloroquine-resistant strains. [1231 
Mannich bases, on the other hand, have received attention in organic chemistry as building 
blocks for nitrogenous molecules [124] and have recently been found to possess marked and 
improved antimalarial properties against multi-drug resistant strains of P. jalciparum. [125] 
Besides, isatin-based Mannich bases too have been reported to possess antibacterial, [91] 
antifungal,[92] antiviral,f93] and anti-HIV, [96] antiprotozoal [94] and antihelminthic activitiesl951 . In 
continuation of our work on isatin derivatives, we designed quinoline-Mannich based precursors 
65 (X=O) and the corresponding thiosemicarbazones 66 (X=Nr\HC(S)NH2). We reasoned that a 
bi-therapeutic strategy, in which a haem-binding 4-aminoquinoline moiety is conjugated to a 
cysteine protease inhibiting isatin moiety, could be advantageous with respect to slowing down 
the emergence of drug resistance. Other non-quinoline Mannich bases were also designed with a 
view to establishing preliminary structure-activity relationships with respect to the role of the 4-
aminoquinoline moiety in the activity against the parasite enzymes and parasites themselves. 
The design principle for quinoline N-Mannich base derivatives against P. jalciparlllll is depicted 
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Figure 15. Chemical structures of 65 and 66 and design principle for quinoline lV-Mannich base derivatives 66 
against P. jalciparum. 
The design principle depicted in Figure 15 is summarised as: 
i). The isatin provides a hydrophobic aromatic ring template potential for binding to the 
hydrophobic sites of the target. 
ii). The thiosemicarbazone moiety has been selected to provide reactive sites (the imine and 
thiol carbonyl) for alkylation of the enzyme cysteine thiolate. This moiety is likely a metal 
chelator in which the hydrazinic nitrogen and sulfur atoms could be involved in binding to 
endogenous iron. This has implications for metabolism within the parasite by inhibiting iron-
dependent enzymes as well as metal-interactive inhibition of Jalcipain-2. The hydrazinic 
nitrogen could also assist in the accumulation within the acidic food vacuole of P. Jalciparum. 
iii). To increase accumulation of the molecule, a piperazine substituent bearing a protonatable 











Results and Discussion 
iv). The 7-chloroquinoline moiety has been proposed from earlier findings that it binds to the 
haematin in the parasite's acidic vacuole thus inhibiting haematin formation and increased in 
accumulation due to the protonable nitrogen. [126] 
3.3.2. Synthesis and Characterization 
3.3.2.1 Synthesis 
Chloro-4-piperazin-1-yl-quinoline, the precursor compound was firstly synthesized in good 
yield (66%) from condensation of 4, 7-dichloroquinoline 67 and piperazine 68 (excess) in N-
methyl-2-pyrrolidine (NMP), to give the target compounds 69, (Scheme 20). Upon the 
preparation of the required secondary amine precursor, we proceeded with the Mannich 
reaction. Mannich reactions can be performed via a one pot direct multicomponent protocol 
requiring isatin, an aldehyde and an amine or via a preformed iminium ion. The latter approach 
was used in this project to prepare 65 and 66. Accordingly, paraformaldehyde (1.0 equiv) and 
chloro-4-piperazin-1-yl-quinoline 69 (1.0 equiv) were dissolved in ethanol and stirred for 30 
mins. The iminiun ion formed in situ was then reacted with selected isatins (Scheme 21a) and 
isatin-3-thiosemicarbazones (Scheme 21 b) in ethanol for 3 hours at room temperature to furnish 
the desired N-Mannich isatin derivatives accomplished in low to excellent yields 26-93%, 
(Table 5). The above mentioned approach was used in the preparation of non-quinoline based 
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Scheme 20. (a) K1CO), Et)N, NMP, 13SoC, 4h, 66.4%. 
o 





65; X=O;(R3)R4=piperazinyl quinoline. 66; X=NNHC(S)NH2; (R3)R4= piperazinyl quinoline. 70; X= 
NNIIC(S)NB2; (R)R
4= Et, pyrrodyl, piperidyl, morpholinyl, N-benzyl piperazinyl and N-phenyl piperazinyL 











Results and Discussion 
Table 5. Data on a series of quinoline and non-quinoline Mannich based isatin derivatives. 
65a-66d 70a-70f 
I 
Compound RI R2 (R3)R4 X Time(hrs) % Yield I m.p (OC) 
I 
--- -.-.. -.-'--'-'- -.---
65a H H - 0 4 93 203-206 
65b Me Me - 0 4 85 209-213 
65c Cl H - 0 4 24 153-157 
65d F H ~ 0 4 94 110-117 
65e Me H .~ 0 4 55 202-203 
65f I H - 0 4 59 151-153 
65g Br H ~ 0 4 48 210-212 
66a H H - NNHC(S)NH2 3 78 216-217 
66b F H ~ NNHC(S)NH2 3 51 233-234 
66c CI H - NNHC(S)NH2 3 86 234-235 
66d Br H - NNHC(S)NH2 3 73 236-237 
66e Me H - NNHC(S)NH2 3 78 232-234 
70a H H NEt2 NNHC(S)NH2 3 54 134-135 
70b H H NNHC(S)NH2 3 95 179-181 
70c H H NNHC(S)NH2 3 90 181-184 
70d H H NNHC(S)NH2 3 92 208-210 
70e H H NNHC(S)NI-h 3 62 187-188 
70f 
HI 
H I~ NNHC(S)NH2 3 
I 












Results and Discussion 
3.3.2.1 Mechanism 
The proposed mechanism involves initial amine addition to the carbonyl group of formaldehyde 
to form an intermediate followed by acid-catalyzed dehydration gives the iminium ion. Since no 







Scheme 22. Mechanism for the formation of iminium ion. 
The Mannich reaction of ketones with acidic a-protons usually proceed via nucleophlic enolate 
anions or enol equivalents which attack the electrophilic iminium ion. In case of isatin, the 
acidic NH proton is involved in a kind of keto-enol tautomerism presumably catalyzed by the 
solvent ethanol. Since the enol is the nucleophilic form, the reaction proceeds via this form. Re-
aromatization provides an additional driving force. 
Target compound 











Results and Discussion 
The structures of compounds were assigned on the basis of spectra data, including IH NMR 
spectra which demonstrated characteristic broad signals at 8 3.25 ppm and 8 2.96 ppm for the 
piperazinyl ethylene protons, a singlet at 8 4.60 ppm for the methylene (-NCH2N-) proton while 
the aromatic protons appeared in the region (:) 8.71-6.80 ppm. Further proof of the correct 
structural assignment of the N-Mannich bases was provided by 13C NMR. Aromatic carbons 
were observed in the region between 8 156.0 -109.0 ppm whilst the Sp3 carbons were observed 
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Figure 15: lH NMR spectrum for 66a in DMSO-do' 
From the spectrum, the appearance of singlets at 0 12.40, 9.04, 8.69 and 4.60 ppm representing 
l\TNH, NH2 and -NCH2N- respeetively in the molecule and other derivatives provided evidence 
for product formation. In the 13C NMR spectra, the appearance of the C=N at (:) 162.6 ppm and 
disappearance of the ketonic C=O at 0 183.0 ppm provided further proof. Infrared spectra 
exhibited C=N stretching vibrations at 1590cm- I and there was complete disappearance of 











2.4 QUINOLINE ETHYLENE ISATIN DERIVATIVES 
2.4.1. Background and Rationale 
Results and Discussion 
As with the Mannich base quinolines derivatives 66a-66c, quinoline ethylene isatin derivatives 
71 were essentially aimed at the malaria parasite in a bi-therapeutic strategy similar to the 
quinoline-Mannich based derivatives. The rationale for this class is two-fold and is depicted in 
Figure 16. 
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Figure 16. Design principle for quinoline ethylene derivatives 71. 
In addition to the common structural features already discussed for Mannich base quinoline 66, 
the additional variable alkyl chain in 71 is important for lipophilicity and avoidance of the 
chloroquine resistance mechanism: 
i). Lipophilicity is an important parameter in the effectiveness of aminoquinoline antimalarial 
agents such as chloroquine. Sufficient lipophilicity is required for these agents to cross the 
parasite membrane and enter the acidic vacuole where they accumulate via pH trapping. 
[127] Thus introducing a variable alkyl spacer between the isatin and 4-aminoquinoline 
moiety would permit studies of the effects of lipophilicity and antimalarial activity within 
a homologous series. Moreover, for metal (iron) chelators, lipophilicity is an important 
property in effective antimalarial activity_ [128] 
ii). As mentioned earlier, modification of the length of the alkyl side chain of chloroquine has 












Results and Discussion 
For the purpose of the MSc programme, preliminary studies focused only on identifying the 
optimum commercially available scaffold while keeping the ethylene linker constant. 
3.4.2.1 Synthesis of Derivatives 75a-75e and 71a-71c 
The quinoline-ethylene isatin derivatives listed in Table 9 were prepared according to Scheme 
24. Reaction of excess 2-amino ethanol 72 and 4, 7-dichloroquinoline 67 as reported previously 
[126) gave 73 in a good yield of 92%. This was followed by o-mesylation [129] in pyridine at 0 °C 
for 5 hours to furnish 74 in a yield of 82%. Selectivity in the mesylation of preformed alcohol 
73 was not a problem in spite of the presence of the 4-amino (NH) group. This is due to the fact 
that the lone pair of electrons on the nitrogen is in conjugation with the quinoline nitrogen and is 
not readily available for reactions. Thus O-mesylation proceeded smoothly at low temperature. 
The reaction could also have proceeded via initial attack of the quinoline nitrogen (DMAP 
effect) on the sulfonyl group of MsCI followed by sulfonyl transfer from the resulting 
intermediate to the primary hydroxyl group. 
The synthesis of quinoline-ethylene isatin derivatives from 74 (as in Scheme 24) employed 
sodium hydride as the base and dimethylformamide (DMF) as the solvent resulted in good 
yields (68-88%) of the products, (Table 6). Selected precursors were used in formation of 














Scheme 24. (a) 0.3 equiv. of K2C03, 0.3 equiv. of Et3N, reflux, 8h, 92 %; (b) 2.5 equiv. of methanesulfonyl 
chloride, pyridine, 0 °c, 5h, 83%;(c) NaH, isatin!5-substituted isatin, DMF, 60°C, 24h, 68-89%; (d) 











Results and Discussion 
It is noteworthy that compounds 71a-71c were prepared from precursors 75a-75e by 
condensation with thiosemicarbazide as shown in Scheme 24 (d). It was necessary that the target 
compounds were prepared using this procedure. The alternative procedure of starting with 
thiosemicarbazone derivatives 64 of isatin followed by alkylation would have led to S-
alkylation at the thiosemicarbazone moiety as a competing reaction to give unwanted product 
77, (Scheme 25). 
64 74 77 
Scheme 25. By product formation via S-alkylation. 
Table 6. Data on a series of ethylene-quinoline isatin derivatives 
x 0 (\(CI 




Rl R2 X Time(brs) %Yield mp (OC) 
i 
---
75a H H 0 16 88 240-243 
75b Me H 0 16 68 240-243 
75c CI H 0 16 69 221-223 
75d Me Me 0 16 89 219 
7Se I H 0 16 70 200-201 
71a H H NNHC(S)NHz 3 70 167-171 


















The structures of the respective analogues were confirmed by iH NMR spectra, below is the IH 
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Figure 17. IH NMR spectrum for 7ta in DMSO-d6. 
The IH NMR spectra as shown in Figure 17 above explains the following; 
i) Presence ofNNH, NH2 
ii) Characteristic triplets for H-l' and H-2' respectively. 
iii) Presence of aromatic protons of isatin and quinoline from b 8.40 - 6.63 ppm. 
iv) Absence of methyl signal of the mesylate at b 3.07 ppm and NH from the isatin at 8 11.20 
ppm. 
The small peaks found at 0 3.90 and 7.50 ppm and marked with an asterisk (*) may be due to 
some unreacted starting material or probably due to E, Z isomerism. 
The other spectroscopic data was satisfactorily and consistent with the structure. The purity for 
most derivatives \vas confirmed by elemental analysis data which was within the acceptable 
=0.4 %). However. a few compounds did not show satisfactory elemental analysis data in respect 












The chemical synthesis of series of derivatives based on isatin scaffold have been investigated. 
N-functionalized isatin derivatives 57a-57i and 58a-58b were synthesized mainly in one-step 
by parallel synthesis using immobilized reagents. The success in the use of KFI AhO) as a 
support bound base augur well for future parallel synthesis of libraries of these derivatives. The 
N-(carbobenzyloxy) isatins 59a-59d were successfully synthesis despite obtaining relatively low 
yields. The reactions involving isatin-3-thiosemicarbazones proceeded accordingly to afford all 
desired products in excellent yields. Bi-functionalized isatin derivatives (quinoline-Mannich 
base and quinoline-ethylene thiosemicarbazones) were synthesized in two or more steps 
involving preformed precursors and all were also obtained in reasonable to excellent yields. 
In view of the prevalence of parasitic diseases in poor third world countries, there is a need to 
consider simple and cost effective synthetic chemistry in order to make potential drugs 
affordable. These considerations should always guide the selection and prioritization of target 
compounds. The importance of simple, cost-effective synthesis cannot be over emphasized for 











Results and Discussion 
CHAPTER 4 
BIOLOGICALEV ALUATION OF SYNTHESIZED COMPOUNDS 
4.1 N-SUBSTITUTED ISATIN DERIVATIVES 
4.1.1.In vitro Activity of N-substituted isatins against Cruzain, Falcipain-2, Rhodesain and 
a chloroquine-sensitive (3D7) strain of P. Jalciparum. 
ICso values against recombinant proteins (cruzain andfalcipain-2) were determined essentially 
as described previously [1041. Accordingly, equal amounts (~1 nM) each of recombinant protein 
was incubated with different concentrations of inhibitors (added from 100x stocks in DMSO in 
100 mM sodium acetate (pH 5.5)-10 mM dithiothreitol for 30 min at room temperature before 
addition of the substrate benzoxycarbonyl-Leu-Arg-7-amino-4-methyl-coumarin (final 
concentration, 25 /-lM). Fluorescence was continuously monitored for 30 min at room 
temperature in a Labsystems Fluoroskan II spectrofluorometer. ICso values were determined 
from plots of activity over inhibitor concentration with GraphPad Prism software. 1Cso values 
for rhodesain were similarly determined at 3nM. Selected compounds from the series were also 
tested against a chloroquine-sensitive 3D7 strain of Pfalciparum. Results of the aforementioned 











Results and Djscussion 
Table 7. Inhibition of cruzain,falcipain-2, rhodesain and chloroquine-sensitive (307) strain by N-substituted i5atin 
and commercially available derivatives. 
ICso ["M] EDsohlM] 
Compound Rl R2 R3 Cruzain Falcipain-2 Rhodesain 3D7d 
methylisatin H H Me >10a NEb NDe ND 
phenylisatin H H Ph >10 NE ND ND 
57a H H >10 NE >10 ND 
57b H 90 ND >10 ND 
57c Me H 80 NE >10 ND 
57d Me H >10 NE >10 69.14 
57e Me H 2 21.9 >10 5.30 
57f Me H 2.8 9.2 >10 9.89 
57g Cl H 6 31.2 >10 ND 
57h CI H >10 34.6 >10 ND 
57i Cl H 90 46.9 >10 7.40 
58a H H >10 NE 100 ).ID 
58b H H >10 NE 15 ND 
59a H H >10 NE 30 ND 
59b CI H 80 NE >10 ND 
59c Me H >10 NE >10 ND 
59d F H >10 NE >10 6.17 











Results and Discussion 
From the in vitro results presented in Table 7 [130], several trends were observed as follows: 
i). In general compounds without a substituent at position 5 (Rl) of isatin (N-methylisatin, N-
phenylisatin, 57a, 58a, 58b and 59a) did not generally show good activity (ICso > 10 11M). 
ii). A combination of N-benzylation and substitution at position 5 seemed favourable and 
exhibited modest to good activity with 57e, 57f and 57g, showing good activity against both 
cruzain and falcipain-2. The best compound in this series was 57f which showed activity 
against two cysteine proteases (jalcipain-2 and cruzain) with ICso values 2.8 11M and 9.2 11M 
,respectively. This compound contains a privileged biaryl substructural unit probably essential 
for activity. 
iii). Alteration of substituents on the isatin and benzyl rings decreased activity against 
falcipain-2, but increased activity against cruzain (57e and 57g). 
iv). Exchanging the N-benzyl for N-acyl and N-sulfonylisatin derivatives had no beneficial 
effect regardless of the substituent (R 1, R 2, R\ 
v). Against the chloroquine-sensitive 307 strain, compounds 57d, 57e, 57f, 57i and 59d 
demonstrate very weak (57d) to moderate (57e, 57f, 57i and 59d) inhibitory activity, while the 
rest were not determined because they were inactive at the initial cut off concentration of 250 
mg/m! chosen for % parasite survival. 
Against the cysteine protease enzymes, the preliminary study revealed that N-benzylated 
scaffolds are favoured to bind the cysteine proteases. As mentioned previously, the benzyl 
moiety was presumed to bind tightly in the S2 pocket of the enzyme and this accounts for the 
increased potency of this class of inhibitors. Apparently, compound 57f (biaryl containing), is 
superior to other derivatives against cruzain and falcipain-2. The biaryl motif is regarded as a 
privileged substructural unit which binds to a wide range of proteins. [131] From this limited 
structure-activity relationship (SAR) data, it is tempting to speculate that isatins containing a 
biaryl moiety might provide ligands for a diverse set of cysteine proteases. However, more 
biaryl compounds will need to be synthesized and tested against multiple cysteine proteases in 











Results and Discussion 
4.2 ISATIN-3-THIOSEMICARBAZONE DERIVATIVES 
4.2.1 Inhibition of Cruzain, Falcipain-2 and Rhodesain 
Table 8. Inhibition of cruzain,falcipain-2 and rhodesain by commercial isatins and thiosemicarbazone derivatives. 
ICso [~M] 
Compound Rl R2 R3 X Cruzain Falcipain-2 Rhodesain 
Isatin H H H 0 > lOa NEb >10 
5-methylisatin Me H H 0 >10 NE NDc 
5-fluoroisatin F H H 0 >10 NE NO 
5-chloroisatin Cl H H 0 >10 NE NO 
5-bromoisatin Br H H 0 >10 NE NO 
5-iodoisatin I H H 0 >10 NE NO 
5-nitroisatin N02 H H 0 >10 42.6 >lO 
5-(CF30) isatin CF3 H H 0 >10 NE >10 
5,7dimethylisatin Me Me H 0 >10 NE NO 
64a H H H N-NHC(S)NH2 8 38.8 3.5 
64b F H H N-NHC(S)NH2 30 38.6 15 
64c Cl H H N-NHC(S)NH2 21 32.8 6 
64d Br H H N-NHC(S)NH2 20 29.6 7 
64e I H H N-NHC(S)NH2 9 28.7 1 
64f Cl Me H N-NHC(S)NH2 10.5 9.4 3 
64g Me H H N-NHC(S)NH2 20-50 43.9 15 
64h Me Me H N-NHC(S)NH2 16 13.2 15 
64i N02 H H N-NHC(S)NH2 30 4.4 17 
64j H H Ph N-NHC(S)NH2 16 29.7 40 
64k H H Me N-NHC(S)NH2 58 63 50 











Results and Discussion 
All inhibitors were screened for effectiveness against the three proteases using procedures as 
described above (4.1.1). The results are presented in Table 8 as IC50 values together with those 
of commercially available isatins which are included for comparison purposes. 
On the account of the biological data presented above in Table 8, the following SAR 
observations were made. [130] 
i). All the commercially available derivatives were practically inactive. 
ii). The synthesized thiosemicarbazones had better activity ranging from moderate to high in 
most cases. Compound 64f exhibited good activity (lOjlM or less) against all the three enzyme 
targets with ICso values of 10.5 11M, 9.4 11M and 3 11M against cruzain, falcipain-2 and 
rhodesain, respectively. 
iii). Besides 64f, compound 64i displayed moderate potency againstfiJlcipain-2, while 64a and 
64e are the most promising scaffolds against crllzain and rhodesain. 
iv). The order of activity against the targets (especially for crllzain and rhodesain) for the 5 
halo substituted analogues is I > Br > CI > F, implying that within this class, a more 
hydrophobic atom at position 5 is favored for activity (compare 64b, 64c, 64d and 64e). 
Since the initial aim of this work was to identify the promising scaffold for future inhibitors 
design, these compounds were not tested further against the parasite sources of the proteases. 
Suffices to note that in terms of future development of parasitic cysteine protease inhibitors 
based on the isatin scaffold, combination of the thiosemicarbazone moiety with N-benzylation 
might lead to superior inhibitors. Moreover, privileged biphenyl-based N-benzylated derivatives 
might provide diverse ligands for multiple parasitic cysteine proteases. The commercial 
availability of a diverse range of boronic acids for construction of the biphenyl (biaryl) moiety 
via the palladium (D)-catalyzed Suzuki cross coupling reaction should facilitate SAR studies in 
this regard. The generally superior activity of thiosemicarbazone derivatives, compared to 
corresponding commercially available ketone precursors, might suggest the involvement of the 
thiocarbonyl (C=S) group in the mechanism of inhibition of the parasitic cysteine proteases 
understudy in this project. This is in line with the mechanism of inhibition of cruzain by simple 
aromatic thiosemicarbazones suggested by Du and co-workers [[04] (also described in Scheme 16 
on page 36). The differences in activity across the proteases gives some indication in 











4.3 MANNIeH AND ETHYLENE BASED ISATIN DERIVATIVES 
4.3.1 Inhibition activity of derivatives 68a-75c 
Results and Discussion 
Compounds in the series 65a-71c were evaluated against cruzain and rhodesain. Percent 
activity which gives a measure of the inhibitory activity of each compound in place of ICso 
values was determined. The lower the % enzyme activity, the more potent a compound is as an 
inhibitor at a given concentration. The results are presented in Table 9. 
As can be seen from the Table 9, 
i). Generally thiosemicarbazones (66a, 66b, 66c, 66e, 71a and 71b) were most effective at 
reducing enzyme activity compared to the corresponding ketone derivatives especially in the 
case of rhodesain. Compound 71 b was found to be very potent against both cruzain and 
rhodesain by reducing the % activity of the enzyme to 23 and 6% respectively. Similarly, 
compounds 66b, 66c, 66e and 71a demonstrated an increased potency and apparently more 
potent against rhode.min (2-4% enzyme activity for the best compounds 66b, 66c and 66e). 
ii). The non-quinoline based derivatives (70a-70f) showed lack of activity against both 
crllzain and rhodesain as compared to their corresponding quinoline based derivatives (66b, 
66c, 66e, 71a and 71h). 
iii). Against crllzain, the quinoline-Mannich base derivatives (66b, 66c and 66e) were less 







































,I Not determined 
Table 9. Percentage Activity of the enzyme in the presence of 1 0 ~IM of compound. 
65a-66c 
RI R2 (R3)R4 
H H ~ 
Me Me ~ 
Cl H ~ 
F H ~ 
Me H .~ 
I H ~ 
Br H ~ 
H H ~ 
Me H ~ 
F H ~ 
Cl H ~ 
Br H ~ 
H H NEt2 
H H " 
H H , 




H H N N Ph 
H H ~ 
Me H ~ 
Cl H -
Me Me ~ 
I H -
H H ~ 









X Cruzaill Rhodesain 
0 55 92 
0 NO NO 
0 NO NO 
0 89 91 
0 NO NO 
0 86 91 
0 NO NO 
N-NHC(S)NHz 86 46 
N-NHC(S)NH2 71 3 
N-NHC(S)Nl-b 76 2 
N-NHC(S)NH2 NO NO 
N-NHC(S)NH2 83 4 
N-NHC(S)NH2 71 67 
N-NHC(S)NH2 82 71 
N-NHC(S)NHz 84 65 
N-NHC(S)NH2 81 78 
N-NHC(S)Nlb 85 74 
N-NHC(S)NH2 92 74 
0 93 83 
0 92 
0 NO NO 
0 92 71 
0 NO NO 
N-NHC(S)NH2 57 10 
N-NHC(S)NH2 23 6 











Results and Discussion 
4.3.2 In vitro Activity of derivatives 65-71 against P. Jalciparum DIO, Kl, and W2 strains 
Since P. Jalciparum malaria was the main focus of the MSc project several compounds were 
selected for in vitro testing against P. Jalciparum strains. The detailed procedure for the 
parasites culture CD 10 and K 1) were conducted according to the methods described by Trager 
and Jensen. [l32J Initial Img/ml stocks of the compounds were made up in DMSO, using the pre-
weighed samples provided, and were diluted in water and finally complete medium on the day 
of the experiment. The highest concentration of DMSO that the parasites were exposed to was 
0.05 %, which had no measurable effect on parasite viability. No attempt was made to 
determine IC50 values greater than 1000 ngmrl. All experiments were performed in duplicate on 
a single occasion using a chloroquine-sensitive strain of P. Jalciparum (D 1 0). The more active 
compounds were also tested against a chloroquine-resistant strain of P. Jalciparum (K 1). The 
parasites were continuously cultured and the parasite lactate dehydrogenase (pLDH) activity 
was used to measure parasite viability as described by Makler et a1. [133] The 50% inhibitory 
concentration (1C50) values for the compounds were obtained from the dose-response curves, 
using non-linear dose-response curve fitting analyses with GraphPad Prism v.3.00 software. 
W2-strain P. falciparum parasites (1 % parasitemia, 2 % hematocrit) were cultured in 0.5 mL of 
medium in 48-well cultured dishes. Appropriate inhibitors from 10 mM stocks in DMSO were 
added to cultured parasites to a final concentration of 20 JlM. From 48-well plates, 125 JlM of 
culture was transferred to two 96-well plates (duplicates). Serial dilutions (l :5) of inhibitors 
were made to final concentrations of 10 11M, 2000 nM, 400 nM, 80 nM, 16 nM, 3.2 nM. 
Cultured were maintained at 37°C for 2 days. The parasites were washed and fixed with 1% 
formaldehyde in PBS. After two days, parasitemia was measured by flow cytometry using the 
DNA stain YOYO-l as a marker for cell survivaL [134] 
A dose-response curve is a plot of log of concentration of a drug against the plots of response 
(enzyme activity) expressed in percentage. The IC50 values (see Table 10) are simply the 
concentration of drug required to cause a response halfway between the Y-axis. Depending on 
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~N~NH_I '" II 
R1~R2 I ~N 
75a-71c 
ICst) hIM] 
R2 (R3)R4 X P. Jalciparum P. Jalciparum P. Jalciparum Falcipain-2 
DI03 K1b W2c 
------ ------ ---------- ------ ----------------
H - 0 0.949 NOe 0.961 >20 
Me - 0 NO NO NO NO 
H - 0 1.069 NO NO NO 
H - 0 0.719 0.720 0.908 >20 
H - 0 NO NO NO NO 
H - 0 0.915 NO 0.794 -20 
H - 0 NO NO NO NO 
H - NNHC(S)NH2 1.370 NO 0.957 9.265 
H - NNHCCS)NH:: NO NO NO NO 
60 
Rid RI 



















66e F H ~ NNHC(S)NH2 1.185 NO 1.193 7.987 1.007 
66d CI H ~ NNHC(S)NH2 1.370 ND 1.809 NO ~ 1.320 
66e Br H ~ NNHC(S)NH2 0.640 0.521 1.226 6.069 0.814 1.916 
70a H H NEt2 NNHC(S)NI-h NO NO »10 >20 ~ 
70b H H NNHC(S)NH2 NO NO »10 >20 ~ ~ 
70e H H NNHC(S)NH2 NO NO »10 >20 - ~ 
70d H H NNHC(S)NI-h NO NO »10 >20 - ~ 
70e H H NNHC(S)NH2 NO NO »10 >20 ~ -
70f H H N-Ph NNHC(S)NI-h NO NO »10 >20 - -
7Sa H H ~ 0 0.905 0.990 0.125 >20 1.094 0.138 
75b Me H - 0 0.547 0.727 0.489 >20 1.329 0.894 
7Sc CI H ~ 0 0.375 1.507 NO NO 4.019 -
75d Me Me - 0 0.330 0.454 0.227 -20 1.376 0.688 
7Se 1 H .- 0 NO NO NO NO -
71a H H - NNHC(S)NH2 0.320 0.712 0.242 14.650 2.225 0.756 
7tb Me H - NNHC(S)NIh 0.079 0.101 0.051 11.640 1.278 0.646 
71e CI H - NNHC(S)NH2 0.095 0.054 ND NO 0.568 -
.. - - ----
CQ 0.033 0.312 0.240 9.454 7.273 












Results and Discussion 
4.3.2.1 Inhibition ofjalcipain-2 by compounds 65a 71c 
i). SAR studies show that quinoline thiosemicarbazone derivatives 66 and 71 that were assayed 
generally showed better inhibition activity against falcipain-2 compared to the corresponding 
ketones 65 and 75, respectively. It is noteworthy that all non-quinoline Mannich base 
thiosemicarbazones 70 were less active (ICso > 20 ).tM) compared to the corresponding quinoline 
Mannich bases 66. This may suggest preference for larger hydrophobic groups in the S2 enzyme 
binding pocket. 
ii). Within the thiosemicarbazones, quinoline-Mannich based derivatives 66a, 66c and 66e more 
active against the enzyme, with IC50 values mostly less than 10 ).tM, compared to the ethylene 
quinolines 71a-7l b albeit there is no direct correspondence in some respective structures with 
regard to substituents. 
iii). Considering compounds that were similar (66a - 66e) with respect to position 5 substituents, 
the general order of activity against falcipain-2 was Br > F > H. This trend is consistent with the 
trend observed for isatin-3-thiosemicarbazones (Table 8, page 56) in which a large (iodo) 
substituent at position 5 resulted in high potency against the enzyme. 
4.3.2.2 Effects of compounds 65a - 71 c on Malaria Parasites DI0, Kl and W2 
In the study of antimalarial effects of compounds 65a- 71e, the following observations were made. 
i). Thiosemicarbazones 71a, 71b, and 71e were generally superior compared to the 
corresponding ketone derivatives 75a, 75b, and 75c. This trend was not observed for the Mannich 
bases 65 and 66. Compounds 7tb and 7tc were particularly active against all three P. falciparum 
strains 0 10, K I and W2. These two compounds were even superior to chloroquine in the resistant 
W2 and K 1 strains, with ICso values of 0.051 j.tM and 0.054 j.tM respectively while still retaining 
respectable activity against 010. 
ii). Within the thiosemicarbazones, the ethylene-based derivatives were comparatively more 
potent than the Mannich bases. For example, compounds 7tb and 7Ic had better ICso values, 











Results and Discussion 
iii). Removal of the quinoline ring system generally resulted in a significant loss of activity 
against all the three parasite strains to a point were it was deeded unnecessary to determine ICso 
values in 010 and K 1 strains for compounds 70a - 70f. Although the ICso values were measured 
against W2, they were much greater than 10 11M. 
iv). Among the more active ethylene-quinoline thiosemicarbazones, methyl substitution at 
position 5 on the isatin ring resulted in better inhibitors of parasite growth against W2. Compound 
71b, with ICso = 0.051 11M, was 5-fold better compared to chloroquine in the same W2 strain. 
Chloro substitution at position 5, as in 71c, also showed excellent inhibitory activity against K J 
with an ICso value of 0.054 11M, which was 6-fold better than chloroquine. Considering compounds 
of series 71 only, the order of antimalarial activity was generally CI > Me >H. The SAR study 
within this class of compounds clearly shows no correlation between inhibition of Jalcipain-2 and 
antimalarial activity. 
We have shown that thiosemicarbazone derivatives of isatin are potent inhibitors of Jalcipain-2 and 
P falciparum strains 010, Kl and W2. Clearly, quinoline-Mannich base isatin derivatives (66a, 
66c and 66e) block enzyme activity at IC so values of less than 10 11M. In a similar manner, 
compounds 71a, 71b and 71c (quinoline-ethylene isatin derivatives) effectively blocked parasite 
development, but had little or no activity against Jalcipain-2. There was no correlation between the 
potencies of compounds againstJalcipain-2 and parasites. This lack of correlation strongly suggests 
that the antimalarial activity of inhibitors 71a, 7tb and 71c were entirely not due to inhibition of 
Jalcipain-2. The biological assays showed no food vacuole abnormalities that usually accompany 
falcipain-2 inhibition. Inhibition ofJalcipain-2 is usually associated with food vacuole swelling due 
to accumulation of undigested hemoglobin that results from blockage of the hydrolysis process. [135J 
Although filicipain-2 appears not to be the principle target for these compounds, it is possible that 
the compounds may be acting through the inhibition of another cysteine protease not contained in 
our (falcipain-2) screen. There are many cysteine proteases in P. falciparum (includingfalcipain-l) 
as already alluded to. The possibility that these compounds may be exerting their antimalarial 
effects through inhibition of another cysteine protease in P. falciparum is supported by the fact that 
compounds 71h and 7lc can bind to and inhibit a cysteine protease. The inhibitory activity (albeit 
weak to modest in some cases) as demonstrated against Jalcipain-2 (weak), cruzain (modest) and 
rhodesain (strong) in Tables 9 and lOis a case in point. Alternatively compounds 71a, 71 b, 71c 











Results and Discussion 
to chelate a transition metal like iron (+2 or +3 oxidation state), it is likely that this mechanism of 
action is responsible for the observed antimalarial activity. Similar conclusions have recently been 
made for tridentate chelating 2-acetylpyridine thiosemicarbazones. [134] 
4.3.2.3 Effects of Different Moieties on Antimalarial Activities 
The excellent inhibitory results against parasite development by compounds 71a, 71b and 71c led 
to our speculating that the improved potency could have been due to the contribution from specific 
moieties which are discussed below: 
a) Effect ofthe Thiosemicarbazone Group 
i). Thiosemicarbazones are potential iron-chelators m P. falciparum, which may exhibit 
biological activity either by withholding iron from plasmodia or by formation of complexes toxic to 
the microorganism. This has implications for iron-dependent enzymes. Withholding iron from such 
enzymes as o-aminolevulinate synthase (enzymes in the heme biosynthetic pathway) results in 
reduction in heme synthesis. [136] This may also lead to the malfunctioning of other iron-dependent 
enzymes such as ribonucleotide reductase which is essential for DNA synthesis. [137,138) This would 
result in the disruption of vital metabol ism and lead to the death of the parasite. Iron chelators such 
as desferrioxamine (DFO), the only agent for clinical use as an iron chelator, have been shown to 
inhibit ribonucleotide reductase activity by binding to the iron. [139, 140] Similarily, the 
thiosemicarbazones may be exerting their antiplasmodial effects through this mechanism. 
ii). Secondly, metal chelators are known to form complexes that subsequently enter the 
erythrocytes to produce a lethal free radical-mediated reaction. One study gives evidence of copper 
complexes of thiosemicarbazones producing oxidative stress upon binding to glutathione, a known 
reducing agent. [141) 
iii). Thirdly, the thiosemicarbazone moiety contains a protonatable hydrazinic nitrogen atom (see 
Figure 16) which possibly increases accumulation in the acidic food vacuole of the parasite via the 











Results and Discussion 
iv). Lastly, the thiosemicarbazone possess an imine (C=N) and a thiol carbonyl (C=S) groups as 
potentia) sites for interaction with a cysteine thiolate in the active site of the cysteine proteases 
(indicated in Scheme 16). 
b) Effect of the Ethylene Linker 
First, introduction of the ethylene linker in the molecule was more favored compared to Mannich 
bases with a piperazinyl linker. The ethylene linker presumably allows the molecule to adopt a less 
restricted conformation due to free rotation, thereby, giving rise to favorable interactions with the 
active site of the target. On the other hand, the piperazinyJ spacer may suffer a loss of rotational 
freedom. 
Secondly, the ethylene linker increases the lipophilicity of compounds 71a, 71b, 71e compared to 
65 and 66. Table 11 summaries the C 10gP (partition coefficient) values of selected Mannich and 
ethylene-based derivatives. C 10gP measures the lipophilicity characteristic of a molecule that 
determines whether the molecule can penetrate and transverse many cell membranes to reach the 
site of action. It is clear that compounds 71a, 71 band 71e have higher C 10gP values which 
probably aids their passage through parasites membranes on the way to their presumed site of 
action, the acidic food vacuole. If these compounds are also exerting their antimalarial effects via 
chelation of iron in P. Jalciparum, then the high lipophilicity is a major contributor. Lipophilicity is 
an important physical property of iron chelators since the iron withheld by chelators from P. 
Jalciparum most likely resides within the parasitic compartment of the malaria infected red blood 
cell. As such an effective antimalarial iron chelator should have the ability to cross lipid membranes 
and display high selective affinity for iron (II) or iron (III) compared to other endogenous transition 
metals. A correlation between the degree of lipophilicity of an iron chelator and its antiplasmodial 
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Table t I. C logP values of selected compounds. 
Compounds ClogP 
65 a 2.88 
65 b 2.57 
65c 3.13 
66 a 4.49 
66 b 4.98 
66d 5.20 
71a 5.15 
71 b 5.65 
71c 5.86 
c) Effect of Quinoline Moiety in the Molecule 
The quinoline moiety may be enhancing the antiplasmodial activity in two ways; 
i). Via increased Iipophilicity (high C logP values) (Table 11). Since the molecules are able 
transverse the membranes of the parasitized erythrocytes to reach the acidic food vacuole and 
accumulate through protonatable nitrogens, which is the basis of the pH-trapping principle. 
ii). Through the inhibition of ~-haematjn formation by the 7-chloro aminoquinoline moiety. [1261 
d) Effect of substituents at position 5 in the isatin moiety 
Chloro and methyl substitution at position 5 on the aromatic ring of the isatin is favored presumably 
for binding to the target. 
4.3.3 Resistance Index 
Resistance index is defined as the ratios of the IC50 against resistant strains (W2 or K 1 in this case) 
to the ICso of the same compound against sensitive strains (e.g. 010). The ratio measures the 
potential of any new compound against chloroquine-resistant strains relative to choloroquine (CQ). 
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RI = Ieso of compound in resistant strain 
Ieso of compound in a sensitive strain 
Relative to eQ, RI greater than CQ indicates a weaker activity against the chloroquine-resistant strains 
(K 1 or W2), while RI less than that of CQ indicates a better activity of the compound against the 
chloroquine-resistant strains (Kl or W2). Most compounds showed indices far less than CQ (Table 10), 
signifying that most isatin compounds 65a-7tc are promising agents against Kl and W2 strains 
Moreover the results suggest that the mechanism of action of these compounds may be different from 
that of chloroquine. 
4.4 Compliance to Lipinki's Rule 
III ,·itro screens for antimicrobial activity provide the capacity of inhibitors against emerging infectious, 
not necessarily how the drugs will work in humans. For the most potent compounds in the tested 
series (57f, 64f, 7tb and 71c) to succeed in animal and human clinical trials as oral drugs depends on 
absorption, distribution, metabolism, excretion and toxicity (ADMET) properties. Lipinki's "rule of 5" 
is used to classify which compounds are likely to have good intestinal absorption (membrane 
absorption or permeability) as a measure of a drug-like compound. [143] The rule states that good 
absorption and permeability is likely when: 
a) Molecular weight < 500 
b) C logP < 5 
c) Number ofH-bond acceptors (expressed as the sum ofNs and Os) :::10. 

















molecular weight: 319.87 
H-bond donors: 1 
H-bond acceptors: 3 
clog p: 5.1 
No. of criteria met:4 
64f 
molecular weight: 268.72 
H-bond donors: 4 
H-bond acceptors: 5 
clog p: 2.4 
No. of criteria met: 4 
71b 
57f 
molecular weight: 327.38 
H-bond donors: 0 
H-bond acceptors: 3 
clog p: 4.4 




molecular weight: 438.93 
H-bond donors: 4 
H-bond acceptors: 7 
clog p: 5.6 
molecular weight: 459.35 
H-bond donors: 4 
H-bond acceptors: 7 
clog p: 5.9 
No. of criteria met: 3/4 NO.criteria met: 3/4 
f'igure 18. Compliance of chloroquine and the most active synthesized compounds to Lipinski's rule of 5. 
A compound that meets at least 3 out of the 4 criteria set by Lipinki's rule of 5 is likely to be 
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4.5 Conclusion 
We have identified various novel molecules that can serve as potential inhibitors against cysteine 
proteases and appropriate parasites. Inhibitor N-biphenyl-2-yl-5-methyl-1 H-indole-2, 3-dione 57f 
from the class of N-substituted isatin derivatives has shown potency against falcipain-2 and 
cruzain. The 5, 7-substituted isatin-3-thiosemicarbazone 64f exhibited promising inhibitory 
activities against the 3 enzymesfalcipain-2, cruzain and rhodesain. In light of these inhibitors, it is 
actually advantageous from a therapeutical viewpoint and can be extremely useful in treating 
numerous parasitic infections, to have compounds acting against targets from multiple protozoan 
parasites, (see Chapter 1.3). Two quinoline-ethylene thiosemicarbazone derivatives N 1-[2-(chloro-
quinolin-4-ylamino) ethylj-5-methyl-1 H-indole-2,3-dione-3-thiosemicarbazone 71 band N 1-[2-(7-
chloro-quinolin-4-ylamino) ethylj-5-chloro-l H-indole-2, 3-dione-3-thiosemicarbazone 71c showed 
improved efficacy compared to chloroquine against the chloroquine-resistant P. falciparum strains 
K I and W2. Further comparisons with chloroquine should be done in vivo even for the not so 
potent compounds. However, it is not clear what the structural features controlling the in vitro 
antimalarial activities are, since there was no correlation with inhibition of falcipain-2, the 
presumed target. Investigations into this class of compounds is therefore further warranted as they 
may prove to be beneficial and will further direct efforts to find even more antimalarial 
chemotherapies in future. A chemical proteomic approach will particularly be useful in identifying 
targets for thiosemicarbazones in P. falciparum. In this regard the synthesis of biotinylated affinity 
probes for use in the affinity purification of protein targets should facilitate the understanding of 
true targets of the most active compounds. This would then be followed by the synthesis of new 
derivative libraries against the new targets identified. Finally it is worth noting that the potentially 















Proton nuclear magnetic resonance e H NMR) spectra were recorded at ambient temperature using 
the following instruments: Varian Mercury (300MHz) or Varian Unity Spectrometer (400MHz) and 
TMS was used as an internal standard. The chemical shifts (8) are given in ppm relative to TMS (8 
0.00). 
Carbon-I3 nuclear magnetic resonance (BC NMR) spectra were recorded at 75MHz or I OOMI-Iz with 
the same internal standard. Diverse solvents were used in the determination of spectra for different 
compounds. The chemical shifts (8) are given in ppm relative to TMS (8 0.00). 
The following abbreviations were used in the 1 H NMR spectra: s, singlet; d, doublet; dd, double 
doublet; ddd, double double doublet; t, triplet; q, quartet; m, multiplet; qd, quartet of doublets; dt, 
doublet of triplet; td, triplet of doublets; ddt, doublet of doublet of triplets; br. broad and J, coupling 
constant. The format used for recording 13C NMR data is that accepted by most international 
journals (including American chemical society journals). In this format chemical shift values 
are simply listed without specific assignment to carbon atoms. 
Mass spectra were recorded by means of a VG micromass 16 F spectrometer at 70eV with 
accelerating voltage 4kV. Accurate masses were determined using a VG-70E spectrometer (at Cape 
Technikon) and VG (Micromass) 70-SE magnetic sector mass spectrometer (at Kent). 
Infrared spectra were measured either in solution form using chloroform or as solids (KBr pellets) or 
Nujol mulls on a satellite FT-IR spectrophotometer. 
Micro (elemental) analysis was performed using a Fisons EA 1108 CHNS-O instrument. 
Melting points were determined by using a Reicher-Jung Thermovar (temperature range 0-350 0c) on 












Column chromatography and preparative layer chromatography (p.l.c), carried out on silica gel 
(Merck Kieselgel 60) were used in purification of samples. 
Reactions were monitored by thin-layer chromatography (tic) using coated silica gel plates, detection 
by an ultra-violet lamp. 
Commonly used solvents were purified and dried accordingly as described in the literature. 
Anhydrous sodium sulphate and anhydrous magnesium sulphate were used in drying of organic 
solvents after extraction. 
Concentration of organic phase (removal of solvents) was achieved by usmg a Buchi Rotary 
Evaporator under reduced pressure. 











A. General procedure for preparation of compounds 57a - 58b 
Isatin 15-substituted isatin (0.2 g, 1.35 mmol) and KF/Ah03 (0.8 g, 5.44 mmol) were mixed in 10 mL 
of anhydrous dichloromethane (DCM). To the resultant mixture was added benzyl, sulfonyl or 
benzoyl halide (0.16 mL, 1.35 mmol) and the reaction mixture was vigorously stirred at 25°C for) 2 
hours, diluted with diethyl ether and filtered. The solvents were removed under reduced pressure. 
Column chromatography (Si02, EtOAc: Hex, 2:8) yielded the desired product. [145] 
o co, 5 ~ 3 1=0 6' h 2 
7 Nl)'1 0' 




N-Benzyl-lH- indole-2, 3-dione 
(0.30g, 95%) obtained as reddish crystals; m.p. 127°C (from MeOH) (lit 124-
125°C) [146]; Rf 0.45 (EtOAc: Hex 2:8); bH (300MHz, CDCh), 7.61 (1 H, dd, J 
1.2 and 7.2, H-4), 7.50 (lH, ddd, J 1.2,7.5 and 7.8, H-6), 7.34-7.25 (5H, m, 
H-2', 3', 4', 5' and 6'), 7.11 (I H, ddd, J 0.6, 7.2 and 7.8, H-5), 6.79 (l H, d, J 
7.5, H-7), 4.93 (2H, s, -NCH2Ar). 
o 
k~~3 ;.; 5, 
ii ' 2 0 
6~~n 
l' ~3' 
6' I ~ 4' 
5' 
N-Benzyl-5-iodo-lH-indole-2,3-dione 
The conditions employed for the preparation of this compound were those 
described in general procedure A. However, 0.73 mmol of isatin and halide 
were used. 
(0.17g, 65 %) obtained as reddish crystals, m.p.140-14] DC; Rf 0.43 (EtOAc: 
57b 
Hex, 3:7); IR (KBr) vmax/cm- I 1739 (keto C=O), 1601 (amide C=O); bH 
(400MHz, CDC h), 7.43 (lH, d,J 1.2, H-4), 7.38-7.24 (5H, m, H-2', H-3', H-4', H-5' and H-6'), 7.13 
(1 H, dd, J l.2 and 7.6, H-6), 6.75 (lH, d, J 7.6, H-7), 4.91 (2H,s, -NCH2Ar); be (CDCb, 75 MHz), 
183.1,158.4,149.9,140.4,138.6,133.5,129.5 (2 x C), 128.3 (2 x C), 127.1, 125.8, 117.3, ] 11.2 and 
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N-(2, 5-Dimcthyl-bcnzyl)-5-methyl-lH-indole-2, 3-dione 
The conditions employed for the preparation of this compound were those 
described in general procedure A. However, 1.24 mmol of isatin and halide 
were used. 
(O.l9g, 54%) obtained as orange crystals; m.p. 159-160 °C; Rr 0.40; (EtOAc 
/ Hex, 3:7); IR (KBr) Ymax/cm- 1 2927 (C-H), 1728 (keto C=O), 1609 (amide 
C=O); DH (400MHz, CDC b), 7.44 (lH, d, J 1.2, H-4), 7.27 (1 H, dd, J 1.2 and 8.0, H-6), 7.09 (I H, d, 
J 7.6, H-5 '), 7.01 (lH, d, J 7.6, H-4'), 6.91 (lH, s, H-2'), 6.56 (lH, d, J 8.0, H-7), 4.86 (2H, s, -
NClhAr); 2.33 (3H, s, CH3-Ar), 2.30 (3H, s, CH3-Ar), 2.27 (3H, s, CH3-Ar); Dc (CDCh, ] 00 MHz), 
183.5,158.4,148.9,138.7,135.9,133.6,132.5,131.8, 130.7,128.6,127.2,125.6,117.7, ]11.0,42.2, 
20.9,20.5 and 18.8; llRMS (EI) Found mlz 279.12570 [Mt C1sH17N02, requires 279.12593. 
o 
;ai 2~3' 1[ 6' ~ 4' 
5' CI 
57d 
N-( 4-chloro-benzyl)-5-methyl-l H-indole-2, 3-dione 
The conditions employed for the preparation of this compound were those 
described in general procedure A. However, 1.24 mmol of isatin and 
halide were used. 
(0.27g, 76%) obtained as orange crystals, m.p. 163-]65 °c (ethanol); Rr 
0.30; (EtOAc: Hex, 3:7); IR (KBr) YmaJcm- 1 ] 730 (keto C=O), 16] 3 
(amide C=O); DH (400MHz, CDCb), 7.42 (lH, d, JO.8, H-4), 7.34 (tH, dd, JO.8 and 8.0, H-6), 7.30 
(2H, d, J 7.6, H-3' and H-5'), 7.26 (2H, d, J 7.6, H-2' and H-6'), 6.96 (l H, d, J 8.0, H-7), 4.87 (2H, s, 
-NCH2Ar); 2.30 (3H, s, CH3-Ar); Dc (CDCb, 75 MHz), ]83.2, 158.3, 148.2, 138.7, 134.1, 133.9, 
133.2 (2 x C), 128.8 (2 x C), 127.6, 125.8, 117.8, 110.5,43.4 and 20.6; HRMS (EI) Found mlz 












o N -(3-Methoxy-benzyl)-5-methyl-l H-indole-2, 3-dione 
~o The conditions employed for the preparation of this compound were those 
6~7h7a N1 described in general procedure A. Il0wever, 1.24 mmol of isatin and 
I 2' 
~o~· il ~i halide were used. 
6,11 h i4' Y (0.21 g, 60%) obtained as orange crystals; m.p. 135-136 °C (from ethanol); 
57e R f 0.46 (EtOAc: Hex, 3:7);IR (KBr) vrnax/cm·
1 1739 (keto C=O), 1612 
(amide C=O); DH (400MHz, CDC h), 7.42 (lH, d, J 1.2, H-4), 7.28 (l H, dd, J 1.2 and 8.0, H-6), 6.98 
(1 H, d, J 8.0, H-4'), 6.95 (1 H, t, J 8.0, H-5'), 6.91 (lH, d, J 8.0, H-6'), 6.85 (I H, s, H-2'), 6.68 (1 H, d, 
J 8.0, H-7), 4.87 (2H, 5, -NClhAr); 3.77 (3H, s, -O-CH3), 2.31 (3H, s, CH3-Ar); Dc (CDCb, 75 
MHz), 183.1, 160.1, 158.0, 148.6, 138.6, 135.6, 130.0, 129.7, 125.6, 119.6, 118.4, 113.3, 113.2, 
112.8,55.3,43.9 and 20.5; HRMS (El) Found mlz 281.10567 [Mt C 17H15N03 requires 281.10519. 
N-Biphenyl-2-yl-5-methyl-lH-indole-2, 3-dione 
4 -1=0 ")Ct. ~a 3 
I' ° The conditions employed for the preparation of this compound were those 
6'" h 2 . 
7 7a N, 2' described in general procedure A. However, 1.24 mmol of isatin and halide 
l' ~3' 
57f 
\ were used. 
// 4' 
6' 5' 
(0.29g, 72%) obtained as red-orange crystals; m.p 159-163 °C (from ethanol); 
Rr0.42 (EtOAc: Hex, 3:7);IR (KBr) vrnaxfcm·
1
, 1733 (keto C=O), 1606 (amide 
C=O); DB (400MHz, CDC h), 7.47 (lH, d,J2.0, H-4), 7.45 (IH, dd,J2.0 and 
8.0, H-6), 7.38-7.28 (9H, m, H-2', H-3', H-4', H-S', H-2", H-3", H-4", H-5/1 and H-6"), 7.15 (lH, d, J 
8.0, H-7), 4.90 (2H, s, -NCH2Ar), 2.25 (3H, s, CH3-Ar); Dc (CDCh, 75 MHz), 183.4, 160.2, 148.9, 
148.0, 147.6, 147.2, 147.0, 137.6, 135.6, 130.2, 129.7, 128.2, 128.1, 127.9, 127.7, 127.2, 125.4, 
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5-Chloro-N-(4-chloro benzyl}-l H-indole-2, 3-dione 
The conditions employed for the preparation of this compound were 
those described in general procedure A. However, 1.10 mmol of isatin 
and halide were used. 
5' (0.21g, 63%) obtained as orange crystals; m.p. 123-126 °c (from 
ethanol); Rr 0.46 (EtOAc: Hex, 2:8); IR (KBr) vmaxicm· 1 1730 (keto 
C=O), 1603 (amide C=O); bH (300MHz, CDCh), 7.56 (I H, d, 12.1, H-4), 7.47 (1 H, dd, 12. J and 8.4, 
H-6), 7.35 (2H, d, 18.4, H-3' and 5'), 7.26 (2H, d, 18.4, H-2' and 6'), 6.71 (1 H, d, 18.4, H-7), 4.89 
57g 
(2H, s, -NCH2Ar); be (CDCI), 75 MHz), 183.4,158.1,148.3, 138.7, 135.1, 133.3, 130.3, 128.7 (2 x 





The conditions employed for the preparation of this compound were 
those described in general procedure A. However, 1.10 mmol of isatin 
and halide were used. 
(0.23g, 70%) obtained as yellow crystals; m.p. 94-96 °c (from 
5' 
57h ethanol); Rr 0.64 (EtOAc: Hex, 3:7);IR (KBr) vmax/cm'! 1733 (keto 
C=O), 1603 (amide C=O); bH (300M Hz, CDCb), 7.56 (tH, d, 11.8, H-4), 7.45 (1 H, dd, 1 1.8 and 8.4, 
11-6),7.23 (lH, t, 17.8, H-5'), 6.89 (lH, d, 17.8, H-6'), 6.85 (lH, d, 17.8, H-4'), 6.82 (IH, s, H-2'), 
6.74 (1 H, d, 1 8.4, H-7), 4.88 (2H, s, -NCH2Ar), 3.77 (3H, s, Ar -0-CH3); be (CDCb, 75 MHz), 
183.6,160.2,158.5,148.9,137.6,135.6,130.2,129.7, 125.3,119.4,118.5,113.4, 113.2,112.3,55.3 



















The conditions employed for the preparation of this compound were those 
described in general procedure A. However, 1.3953 mmol of isatin and halide 
were used.(0.21g, 70%) obtained as orange crystals; m.p.139-141 °c (lit 140 
DC) [147J; Rf 0.5 (EtOAc: Hex, 3 :7); OH (300MHz, CDC b), 7.58 (I H, d, J 2.1, 
H-4), 7.44 (1 H, dd, J 2.1 and 8.4, H-6), 7.38-7.26 (5H, m, H-2', H-3', H-4', 
H-5' and H-6'), 6.73 (l H, d, J 8.4, H-7), 4.92 (2H, s, -NCH2Ar). 
rt\
0 
5, ~3 3 
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4' 
58a 
N-Pbenylsulfonyl-lH- indole-2, 3-dione 
The conditions employed for the preparation of this compound were those described 
in general procedure A. However, 1.3953 mmol of isatin and halide were used. 
(0.33g, 84%) obtained as orange crystals; mp 185-187 °c (lit 186.5-187 0c) [1481; Rr 
0.35 (EtOAc: Hex, 3:7); OH (300MHz, CDC h), 8.12 (IH, d, J 7.8, H-7), 8.04 (IH, 
dd, JO.9 and 7.4, H-4), 7.92 (l H, ddd, J 0.9,6.9 and 7.8, H-6), 7.65-7.55 (5H, m, H-
2',3',4',5' and 6'), 7.32 (tH, ddd, J 1.2, 6.9 and 7.4, H-5). 
N-Bcnzoyl-lH-indolc-2, 3-dionc 
The conditions employed for the preparation of this compound were those 
described in general procedure A. However, 1.3953 mmol of isatin and halide 
were used. 
58b 
(0.16g, 48%) obtained as orange crystals, mp 210-214 °c (lit 209-211 0c) [149 
1501; Rr 0.47 (EtOAcl Hex, 3:7); OH (300MHz, CDCh), 8.15 (I H, d, J 7.2, H-
7),7.78 (lH, dd,JO.6 and 7.8, H-4), 7.69 (lH, ddd, JO.6, 7.2 and 7.8, H-6), 7.56-7.51 (5H, m, H-2', 
3',4',5' and 6'), 7.36 (I H, ddd, J 1.2, 7.2 and 7.8, H-5). 
B. General procedure for the preparation of compounds 59a-59d 
Isatin or 5-substituted isatin (0.2 g, 1.35mmol) was dissolved and stirred in CLhCN (lOmL) at 0 nC. 
Benzyl chloroformate (0.21 mL, 1.49mmol) was added, followed by 4-dimethylaminopyridine 
(0.012 mL, O.135mmol) and triethylamine (0.20 mL, 1.49mmol). After 3 hours, the resulting mixture 
was removed from ice-bath and 20mL of water was added and a precipitate formed which was 















2, 3-Dioxo-2, 3-dihydro-indole-l-carboxylic acid benzyl ester 
(0.37g, 97%), obtained as yellow crystals; mp 152-154 °c (from ethanol) 
(lit 154-156 0c) [151]; Rf 0.5 (MeOH: EtOAc, 2:8); OH (300MHz, CDC1}); 
8.15 (IH, d, J 8.4, H-7), 7.78 (lH, dd, JO.6 and 7.8, H-4), 7.74 (lH, ddd, 
JO.6, 7.5 and 8,4, H-6), 7.54-7.35 (5H, m, H-2', H-3', H-4', H-5' and 6'), 
7.32 (U-I, ddd, JO.9, 7.5 and 7.8, H-5), 5.48 (2H, s, ArCH20-). 
5-Chloro-2, 3-dioxo-2, 3-dihydro-indole-l-carboxylic acid benzyl ester 
The conditions employed for the preparation of this compound were 
those described in general procedure B. However, 1.10 mmol of isatin 
and benzyl chloroformate were used. 
(0.07g, 19%) obtained as orange crystals, mp 166°C (from ethanol); Rr 
3' 
0.48 IR (CHCI3) vmax/cm-1 1780 (ester C=O), 1745 (keto C=O), 1601 
59b (amide C=O); OH (300MHz, CDCI3); 8.13 (lH, d,J8.7, H-7), 7.72 (lH, 
d, J2,4, H-4), 7.68(lH, dd, J2,4, 8.7, H-6), 7.49-7.38 (5H, m, H-2', H-3', H-4', H-5' and H-6'), 5,47 
(2H, s, ArCH20-); oc(75 MHz); 183.8, 166.7, 156.2, 144.0,138.8,129.1,128.7 (2 x C), 128.4, 128.1 
(2 x C), 127.3, 123.6, 118.6, 117.3 and 68.9; HRMS (EI) Found mlz [M+], 315.02633 C I6H IOCIN04 
requires 315.02984. 
cia 5-Methyl-2, 3-dioxo-2, 3-dihydro-indole-l-carboxylic acid ester The conditions employed for the preparation of this compound were ~UN 
7 I those described in general procedure B. However, 1.24 mmol of isatin 
O~O~ )f 0' and benzyl chloroformate were used. 
6'() 3' (0.09g, 24%) obtained as yellow crystals; mp 144-150 °C (ethanol); Rf 
59c 5' 4' 0.43; IR (CHCb) vmax/cm- I 1780 (ester C=O), 1745 (keto C=O), 1602 
(amide C=O); iSH (400MHz, CDCh); 8.01 (IH, d,J8.8, H-7), 7.55 (lH, d,J2.2, H-4), 7,54 (lH, dd,J 
2.2 and 8.8, H-6), 7.42-7.35 (5H, m, H-2', H-3', H-4', H-5' and H-6'), 5.46 (2H,s, ArCH20-), 2.38 
(3H,s, CH3-Ar); iSc(75 MHz); 183.0, 166.4, 156.0, 143.8, 138.4, 129.2, 128.7 (2 x C), 128.3, 127.3 (2 



















5-Fluoro-2, 3-dioxo-2, 3-dihydro-indole-l-carboxylic acid benzyl ester 
The conditions employed for the preparation of this compound were 
those described in general procedure B. However, 1.21 mmol of isatin 
oAo-» and chloroformate were used. 
6(,)3' (0.12g, 35%) obtained as orange-yellow crystals; mp > 350 DC (from 
59d 5' 4' ethanol); Rf 0.47;IR (CHCh) vmaxlcm·
1 1780 (ester C=O), 1745 (keto 
C=O), 1602 (amide C=O); DH (400MHz, CDCh); 8.18 (lH,d,.f 8.4, H-7), 7.50 (lH, d, .f2.1, H-4), 
7.54 (lH, dd, .f2.1 and 8.4, H-6), 7.39-7.32 (5H, m, H-2', H-3', H-4' and H-5'), 5.36 (2H,s, ArCH20-
); DeC75 MHz); 183.8, 167.0, 156.1, 142.9, 139.5,128.2,127.4 (2 x C), 127.1, 127.0 (2 x C), 125.6, 
124.8, 119.9, 117.1 and 69.6; HRMS (El) Found mlz 299.05963 [Mr, C 16H lOFN04 requires 
299.05939. 
C. General procedure for preparation of compounds 64a-64k 
Equimolar quantities of isatin or substituted isatin (0.2 g, 1.36 mmol) and thiosemicarbazide (0.12 g, 
1.36 mmol) in 10 mL of warm 95% ethanol were stirred at 45°C for 3-4 hours. After standing for 
approximately 24 hours at room temperature, the crystalline products were separated by filtration, 
washed with ethanol, dried and recrystallised from ethanoL 
S 
j--NH2 I-H-Indole-2,3-dione-3-thiosemicarbazone 
N-NH (0.13g, 43%) obtained as orange crystals; m.p. 249-253 °c (from ethanol) 
~v.D4 13 
6~ h /2° (lit 247-249 0c) [152]; DH (400MHz, DMSO-d6), 12.46 (lH, s, NNH), 11.15 
7a N1 
7 H (1 H, s, H-l), 8.98 (1 H, s, NHH), 8.62 (1 H, s, NHH), 7.64 (I H, dd,.f 1.2 and 
64a 7.5, H-4), 7.34 (I H, ddd, .f 1.2, 6.9 and 7.8, H-6), 7.09 (lH, ddd,.f 0.9, 6.9 












5-Fluoro-lH- Indole-2, 3-dione-3-thiosemicarbazone 
The conditions employed for the preparation of this compound were 
those described in general procedure C. However, 1.12 mmol of isatin 
o and thiosemicarbazide were used. 
7 (0.24g, 82%) obtained as yellow crystals; mp 287-289 °c (from 
64b ethanol); IR (KBr) vmax/cm- I 3417 (N-H), 3272 (N-H), 1677 (C=O), 
1611 (C=N), 113 7(C=S); 8J-! (300MHz;DMSO-d6); 12.37 (l H, s, NNH), 11.17 (l H, s, H-I), 9.07 (1 H, 
s, NHH), 8.72 (lH, s, NHH), 7.50 (IH, d,J2.7, H-4), 7.17 (lB, dd,J2.7 and 8.4, H-6), 6.90 (lH, d,J 
8.4, H-7); 8c(75 MHz); 179.5, 163.4, 160.1, 157.7, 139.3, 132.1, 122.2, 119.2, 112.8; LRMS (El) mlz 
238 [60 %, M+], 210 [100 %, M-CgH7FN4S] and 122 [25 %, M-C7HsFN); Anal. Ca\cd. for 
C91-bFN40S C 45.4%, H 2.9%, N 23.5%, S 13.5%. Found C 45.4%, H 2.8%, N 23.5%, S 13.2%. 
5-Chloro-lH- indole-2, 3-dione-3-thiosemicarbazone 
The conditions employed for the preparation of this compound were 
o those described in general procedure C. However, 1.10 mmo! of isatin 
and thiosemicarbazide were used. 
64c (0.20g, 73%) obtained as orange crystals; mp 283-285 °c (from ethanol) 
(lit. 266°C) [153 1; 8H (300MHz; DMSO-d6); 12.62 (IH, s, NNH), 11.22 (lH, s, H_-I), 8.54 (IH, s, 
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7 H 
The conditions employed for the preparation of this compound were 
those described in general procedure C. However, 0.88 mmo) of isatin 
and thiosemicarbazide were used. 
64d (O.llg, 43%) obtained as orange crystals; mp 281-284 °c (from ethanol) 
(lit 270°C) [1541; 8H (300MHz; DMSO-d6); 12.29 (Il-I, s, NNH), 11.26 (IH, s, H-I), 9.07 (IH, s, 


















S /C/ 7a N1 
The conditions employed for the preparation of this compound were those 
described in general procedure C. However, 0.73 mmol of isatin and 
thiosemicarbazide were used. 
7 H 
(0.1 3g, 67%) obtained as orange crystals; mp 265°C (from ethanol) (lit 266-
64e 268°C) [iSS]; bH (300MHz;DMSO-d6); 12.30 (l H, s, NNH), 11.20 (l H, s, H-
I), 8.99 (I H, s, NHH), 8.74 (1 H, s, NHH), 8.03 (I H, d, J 1.8, H-4), 7.67 (I H, dd, J 1.8 and 8.4, H-6), 
6.76 (1 H, d, J 8.4, H-7). 
S 5-Chloro-7 -methyl-l H- J ndole-2, 3-dione-3-thiosemicarbazone 
't-NH2 The conditions employed for the preparation of this compound were 
N-NH 
those described in general procedure C. However, 1.02 mmol of isatin 
o 
and thiosemicarbazide was used. 
64f 
(0.27g, 98%) obtained as yellow crystals; mp > 350°C (from ethanol); 
IR (KBr) Vmax!cm,1 3412 (N-H), 3258 (N-H), 1677 (C=O), 1612 (C=N), 
1130 (C=S); bH (300M Hz; DMSO-d6); 12.11 (lH, s, NNH), 11.02 (lH, s, H-I), 9.57 (lH, s, NHH), 
8.66 (I H, s, NHH), 7.58 (l H, d, J 1.5, H-4), 7.23 (l H, d, J 1.5, H-6), 2.21 (3H, s, CH3-Ar); oe (75 
MHz); 178.7, 162.7, \39.7, 131.3, 126.4, 122.3,121.3,117.9,112.6 and 20.7; LRMS (EI) mlz 268 
[64 %,M+], 240 [100 %, M-C9H9CIN4S1 and 165 [29 %, M-C8H6CIN2]; Anal. Calcd. for 
C IOH9CIN40S C 44.7%, H 3.4%, N 20.9% S 11.9%. Found C 44.7% H 4.3% N 17.1% S 9.7%. 
5-Methyl-l H- indole-2, 3-dione-3-thiosemicarbazone 
The conditions employed for the preparation of this compound were those 
described in general procedure C. However, 1.24 mmol of isatin and 
thiosemicarbazide were used. (0.22g, 74%) obtained as red crystals; mp 
281-283 °c (from ethanol); IR (KBr) vmax!cm,l 3418 (N-H), 3286 (N-H), 
64g 1696 (C=O), 1606 (C=N), 1127 (C=S); OH (400MHz; DMSO-d6); 12.44 
(lH, s, NNH), 11.00 (IH, s, H-I), 8.90 (IH, s, NHH), 8.55 (lH, s, NHH), 7.47 (IH, d, J 1.2, H-4), 
7.15 (I H, dd, J 1.2 and 8.0, H-6), 6.80 (1 H, d, J 8.0, H-7), 2.27 (3H, s, CH3-Ar); oc(75 MHz); 179.4, 
163.3,140.8,132.8,132.3,132.0,122.0,120.6,111.4 and 21.2; LRMS (EI) mlz 234 [54 %, M+], 206 
[100 %, M-C9HION4S] and 146 [34 %, M-CsHsN3]; Anal. Calcd. for C ioHION40S C 51.3%, H 4.3%, 
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5, 7-Dimethyl-l H- indole-2, 3-dione-3-thiosemicarbazone 
The conditions employed for the preparation of this compound were those 
described in general procedure C. However, 1 .14 mmol of isatin and 
thiosemicarbazide were used. (0.25g, 90%) obtained as orange crystals; 
mp 286-287 DC (from ethanol); IR (KBr) Vrnax!Cm- 1 3463 (N-H), 3267 (N-
H), 1688 (C=O), 1605 (C=N), 1124 (C=S); OH (300MHz; DMSO-d6); 
12.49 (IH, s, NNH), 11.12 (IH, s, H-l), 8.95 (lH, s, NHH), 8.60 (lH, s, NHH), 7.32 (lH, d, J 1 H-
4),6.98 (lH, d, J 1.2, H-6), 2.25 (3H, s, CH3-Ar), 2.17 (3H, s, CH3-Ar); Oc (75 MHz); 179.3, 163.8, 
139.4,133.8,133.2,131.9,120.8, 120.4, 119.5,21.2 and 16.5; LRMS (EI) mlz 248 [57 %, M+J, 220 
[100 %, M-C9HI2N4S] and 160 [30 %, M-C9HlON3]; Anal. Calcd. for CIlHl2N40S C 53.2%, H 
4.9%, N 22.6%, S 12.9%. Found C 51.4%, H 3.1 %, N 21.8%, S 13.3%. 
5-Nitro-IH- indole-2, 3-dione-3-thiosemicarbazone 
The conditions employed for the preparation of this compound were those 
described in general procedure C. However, 1.04 mmol of isatin and 
thiosemicarbazide were used. 
64i 
(0.24g, 88 %) obtained as orange crystals; mp >350 DC (from ethanol), IR 
(KBr) vrnax!cm- I 3358 (N-H), 3286 (N-H), 1696 (C=O), 1606 (C=N), 1127 
(C=S); OH (300MHz; DMSO-d6); 12.22 (lH, s, NNB), 11.76 (IH, s, H-I), 9.16 (IB, s, NHH), 9.01 
(l H, s, NHH), 8.59 (l H, d, J 1.2, H-4), 8.27 (l H, dd, J 1.2 and 8.7, H-6), 7.12 (l H, d, J 8.7, H-7); be 
(75 MHz); 178.8,162.8,147.3,142.3,132.6,129.9,120.9,116.3 and lll.l; LRMS (EI) mlz 265 [50 
%, M+], 237 [100 %, M-CsH7Ns02S]; Anal. Calcd. for C9H7Ns03S C 40.7%, H 2.6%, N 26.4%, S 
















The conditions employed for the preparation of this compound were those 
described in general procedure C. However, 0.89 mmol of isatin and 
thiosemicarbazide were used. (0.20g, 76%) obtained as yellow crystals; mp 
245-249 °c (from ethanol) (lit 250-256 0c) [1561; 8H (400MHz;DMSO-d6); 




7 6a l' 6' / ,1' 
5'~ ! 3' 
4' 
64j 
1.2 and 7.6, H-4), 7.59-7.49 (5H,m, H-2', H-3', H-4', H-5' and H-6'), 7.37 
(1 H, ddd, J 1.2, 6.8 and 7.6, H-6), 7.21 (I H, ddd, J 0.8, 6.8 and 7.6, H-5), 6.83 (1 H, d, J 7.6, 1-1-7). 
S I-Methylindole-2,3-diolle-3-thiosemicarbazone 
l-NH2 
4 N-NH The conditions employed for the preparation of this compound were those 
5aJ=~a 3
/
/ 2 described in general procedure C. However, 1.24 mmol of isatin and I -0 
6 ~7a N1 thiosemicarbazide was used. 
7 I 
(0.28g, 97%) obtained as yellow crystals; mp 253°C (from ethanol) (lit 
64k 244 0C)[157, 1581; DH (300MHz;DMSO-d6); 12.40 (1 H, s, NNH), 9.03 (1 H, 
s, KHH), 8.67 (1 H, s, NHH), 7.70 (lH, dd, J 1.2 and 7.8, H-4), 7.44 (1H, ddd, J 1.2,6.9 and 7.8, H-
6),7.17 (lH, ddd,JO.6, 6.9 and 7.8, H-5), 7.13 (lH, d,J 7.8, H-7), 3.21 (3H, s, -NCH3)' 
69 
7-Chloro-4 -piperazin-l-yl-quinoline 
A mixture of 4,7-dichloroquinoline (2.0g, 10.10 mmol), piperazine (4.35g, 
50.49 mmol), K2C03 (0.419g, 3.03 mmol), triethylamine (0.423 mL, 3.02 
mmol) in N-methyl-2-pyrrolidinone (lOmL) was stirred under nitrogen at 135 
CI °c for 4 hours. After cooling to room temperature, the mixture was diluted with 
CH2Ch (50 mL) and washed with brine (10 x 50 mL). The organic layer was 
separated, dried over sodium sulfate, filtered and concentrated. Column chromatography (Si02; 
MeOH: EtOAc, 2:80) yielded the amine 33 (1.87g, 67 %) as a white solid; mp 113-114 °c (from 
methanol) (lit. 113-115 DC) 11 591; Rf 0.34 (MeOH: EtOAc, 2:8); DH (300MHz; CDCb); 8.70 (I H, d, J 
5.1, H-2'), 8.02 (J H, d, J 2.1, H-8'), 7.93 (lH, d, J 9.0, H-5'), 7.40 (I H, dd, J 2.1 and 9.0, H-6'), 6.81 
(lH, d, J 5.1, H-3'), 3.17-3.12 (8H, br s, H-2 and H-3); be (75 MHz); 157.3, 151.9, 150.2,134.8, 
128.9,126.1,125.2,121.9, 108.9,53.5 (2 x C) and 46.1 (2 x C); LRMS (EI) mlz 247 [66 %, M+] and 
205 [100%, M-CIIH10N2CI]; Anal Ca\cd. for C 13H I4N 3C) C 63.0%,H 5.7%, N 16.9% Found C 












D. General procedure for preparation compounds 65a-65g 
To a solution of isatin or substituted isatin (O.2g, 1.35 mmol) in 5mL of 99.9 % ethanol was added to 
a mixture of compound 69 (0.27g, 1.35 mmol) and aqueous formaldehyde 37% (0.03 mL, 1.35 
mmol) also dissolved in lOml of 99.9 % ethanol. The reaction mixture was stirred for 3 hours at room 
temperature, refrigerated for 48 hours to form crystals. The crystalline products were separated by 
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(0.51 g, 93%) obtained as reddish-orange crystals; mp 203-206 
°C (from ethanol); IR (KBr) vmax!cm· J 1730 (keto C=O), 1617 
(amide C=O), 1572 (C=N); DH (300MHz; CDCh); 8.70 (lH, d, J 
5.1, H-2"), 8.02 (I H, d, J 2.1, H-8"), 7.92 (1 H, d, J 9.0, H-5"), 
7.66 (lH, dd, J, 0.6 and 8.0, H-4), 7.62 (IH, ddd, J 0.6,6.8 and 
7.8, H-6), 7.43 (IH, dd, J2.1 and 9.0, H-6"), 7.19 (lH, ddd, J 
0.9,6.8 and 8.0 and H-5), 7.10 (IH, d, J7.8, H-7), 6.82 (lH, d, J 5.1, H-3"), 4.60 (2H, s, -NCH2N-), 
3.24 (4H, br s, -N(Cl-hCHz)2NAr), 2.95 (4H, br s, -N(CH2CH2)2NAr); Dc (75 MHz); 182.1, 159.0, 
156.6, 151.8, 151.5, 150.1, 138.4, 128.9, ]28.4, ]26.3, 125.4, 125.2, 124.0, 121.8, 117.4, 111.5, 
109.1,62.3,51.8 (2 x C) and 50.6 (2 x C); HRMS (FAB) Found mlz 407.12661 [M+lt, 
C22Hl902N4CI requires 407.12747; Anal Calcd for C22HI902N4CI C 64.4%, H 4.7%, N J 3.3%. 
Found C 64.6%, H 4.5%, N 13.3%. 
o 
~o 
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N 1-{4-(7-Chloro-q uinolin-4-yl)-piperazin-l-ylmethyIJ-5, 7-
dimethyl-lH-indole-2,3-dione 
CI The conditions employed for the preparation of this compound 
were those described in general procedure D. However, 1. J 4 
mmol of isatin and compound 69 were used. 
(0.42g, 85%) obtained as red crystals; mp 209-213 °c (from 
ethanol); IR (CHCI 3) Vmax /cm-
J 
] 739 (keto C=O), 1635 (amide C=O), 1542 (C"'"N); OH (400MHz; 
CDeb); 8.71 (lH, d,J5.2, H-2"), 8.02 (lH, d,J2.0, H-8"), 7.93 (IH, d,J9.0, H-5"), 7.43 (lH, dd, J, 
2.0 and 9.0, H_6/), 7.31 (1 H, d, J 2.0, H-4), 7.20 (1 H, d, J 2.0, H-6), 6.80 (1 H, d, J 5.2, H-3"), 4.5 J 












CH3)' 2.29 (3H, s, Ar-CH3); Oc (75 MHz); 182.7, 159.0, 157.7, 151.1, 150.1, 138.9, 134.9, 128.8, 
128.7, 126.8, 125.9, 125.6, 125.0, 122.2, 118.4, 111.8, 109.8, 62.4, 52.8 (2 X C), 50.6 (2 X C), 20.1 
and 19.1; LRMS (El) mlz 434 [58 %, M"'], 119 [100 %, M-CsH9N]; Anal. Caled. for C24H2302N4CI 
C 66.3%, H 5.3%, N 12.9%. Found C 67.3%, H 5.5%, N 12.3%. 
a N 1-[4-(7 -chloro-q uinolin-4-yl)-piperazin-l-ylmethylJ-5-
CI 4 3a 3 
5 ~ 2 chloro-lH-indole-2,3-dione 
Fa 
6 7 ~7a l 2' 6" The conditions employed for the preparation of this compound 
N~I' 5" / I CI were those described in general procedure D. However, 1.10 
r:.t.' 4a" 8" 
3' 4"1 ~ 8a" mmol of isatin and compound 69 were used. (0.13g, 24%) 
65c 3"yN,,, obtained as orange crystals; mp 153-157 °C (from ethanol); IR 
Vma.x !em'] 1736 (keto C=O), 1617 (amide C=O), 1511 (C=N); OH (300MHz; CDCh); 8.69 (1 H, d, J 
5.0, H-2/1), 8.00 (lH, d, J2.0, H-8"), 7.89 (IH, d, J8.8, H-5"), 7.61 (lH, d, J2.4, H-4), 7.57 (IH, dd, 
J 2.4 and 8.4, H-6), 7.42 (1 H, dd, J2.0 and 8.8, H-6"), 7.09 (I H, d, J 8.4, H-7), 6.80 (I H, d, J 5.0, H-
3/1),4.57 (2H, s, -NCH2N-), 3.21 (4H, br s, -NCH2CIl2NAr), 2.91 (4H, br s,-NCH2CH2NAr); oc(75 
MHz); 181.9, 158.3 , 156.6, 151.7, 149.9, 149.5, 138.8, 128.9, 128.4, 126.3, 125.2, 124.9, 123.7, 
121.7,118.4,112.9,109.1,62.4,51.8 (2 X C) and 50.6 (2 x C); LRMS (El) mlz 440 [3 %, M+], 260 
[100 %, M-CI4HISCIN3] ; Anal. Calcd. for C22HIS02N4Cb'H20 C 57.6%, H 4.1%, N 12.2%. Found 
C 57.6%, H 4.1%, N 11.9%. 
a 
F 3.a 31 ~
' 
5i~· 2 a 
6~N1 
7 l 2' 6" 1 ' N1' 5"/ i 
65d 
2'~~' 4a" I 8" 
3' 4" I ~ 8a" 




The conditions employed for the preparation of this compound 
CI were those described in general procedure D. However, 1.21 
mmol of isatin and compound 69 were used. (0.49g, 94%) 
obtained as orange crystals; mp 110-117 DC (from ethanol); lR 
(CHCb) Vmax fcm,l, 1744 (keto C=O), 1615 (amide C=O), 1562 
(C=N); iSH (400MHz; CDCh); 8.70 (I H, d, J 5.2, H-2/1), 8.03 (lH, d, J 2.0, H-8"), 7.90 (I H, d, J 9.0, 
H-5"), 7.42 (lH, dd, J2.0 and 9.0, H-6/1), 7.35 (lH, d, J2.1, H-4), 7.31 (IH, dd, J2.1 and 8.2, H-6), 
7.11 (lH, d, J 8.2, H-7), 6.82 (lH, d, J 5.2, H-3"), 4.58 (2H, s, -NCH2N-), 3.25 (4H, br s, -
NCH2CH2NAr), 2.93 (4H, br s, -NCH2CH2NAr); oe (75 MHz); 181.9, 159.6,156.7,151.8,150.1, 












50.8 (2 X C); HRMS (FAB) mlz 425.11703 [M+lt C22HlsCIFN402 requires 425.11805; Anal. Calcd. 






7 I The conditions employed for the preparation of this compound 
"'J'.~ 6" CI 
N r 5"? " I ... \' 4 .. I were those described in general procedure D. However, 1.24 
2'~1'II. a 8" 
3' 4" ~ Sa" mmol of isatin and compound 69 were used. (0.29g, 55 %) 
3" / N1" 
65e 2" obtained as reddish-orange crystals; mp 202-203 °c (from 
ethanol); IR (CHCb) Vmax /cm-
1, 1729 (ketone C=O), 1609 (amide C=O), 1518 (C=N); OH (300MHz; 
COCh); 8.69 (l H, d, J 5.1, H-2"), 8.02 (I H, d, J 2.1, H-8/1), 7.90 (1 H, d, J 8.7, H-5"), 7.45 (I H, d, J 
2.4, H-4), 7.43 (lH, dd, J2.4 and 7.8, H-6), 7.38 (lH, dd, J2.1 and 8.7, H-6"), 7.02 (lH, d, J7.8, H-
7),6.81 (1 H, d, J 5.1 ,H-3/1), 4.58 (2H, s, -NClhN-), 3.24 (4H, br s, -NCH2CH2NAr), 2.94 (4H, br s, -
NCH2ClhNAr), 2.35 (3H, s, Ar-CH3); oc(75 MHz); 182.4, 159.1, 156.6, 151.5, 150.7,150.2,138.4, 
128.8,128.4,126.4,125.7,125.6,124.4,121.8,118.2, 110.5, 109.0,62.3,51.6 (2 x C), 50.6 (2 x C) 
and 21.2; HRMS (FAB) Found mlz 421.14346 [M+lt C23H21CIN402 requires 421.1431 . Anal. 




6 ~7a N1 The conditions employed for the preparation of this compound 
7 • 2' 6" 
'" l' CI N~'. 5"? I" were those described in general procedure D. However, 0.73 
2'~~ 4a" S" f . d d 
3' 4" i ~ Sa" mmol 0 Isatin and compoun 69 was use. (0.23g, 59%) 
3" i ;.: N1" obtained as red crystals; mp 151-153 °c (from ethanol); IR 
65f (CHCb) Vmax /cm-
J 1745 (keto C=O), 1602 (amide C=O), 1536 
(C=N); OH (400MHz; COCI3); 8.68 (l H, d, J 5.2, H-2/1), 8.02 (lH, d, J 2.0, H-8/1), 7.94 (1 H, d, J 9.0, 
H-5"), 7.93 (I H, d, J 0.3, H-4), 7.90 (I H, dd, J 0.3 and 8.0, H-6), 7.43 (1 H, dd, J 2.0 and 9.0, H-6"), 
6.94 (III, d, J 8.0, H-7), 6.81 (lH, d, J 5.2, H-3"), 4.58 (2H, 5, -NCH2N-), 3.22 (4H, br s, -
NCl-hCH2NAr), 2.92 (4H, br S, -NCH2CH2NAr); Dc (75 MHz); 181.6, 158.6, 156.9, 151.8, 150.7, 
150.0,136.7,135.8,128.8,126.4,124.9,124.5,123.9, 121.8, 119.2, 113.7, 109.1,62.4,51.8 (2 x C) 















CI The conditions employed for the preparation of this compound 
were those described in general procedure D. However, 0.88 
mmol of isatin and compound 69 were used. 
(O.2lg, 48%) obtained as orange crystals; 111p 210-212 °C (from 
ethanol); IR (CHCI]) V max /cm'l 1736 (keto C=O), 1618 (amide C=O), 1502 (C=N); brl (300MHz; 
CDCb); 8.70 (JH, d, J 5.1, H-2"), 8.02 (lH, d, J 2.1, H-8"), 7.90 (lH, d, J9.0, H-5"), 7.72 (IH, d, J 
2. L H-4), 7.55 (IH, dd, J 2.1 and 8.4, H-6), 7.42 (lB, dd, J 2.1 and 9.0, H-6"), 7.05 (lH, d, J 8.4, H-
7),6.82 (1 H, d, J 5.2, H-3"), 4.58 (2H, s, -NCH2N-), 3.24 (4H, br s, -NClhCH2NAr), 2.93 (4H, br s, -
NCH2CH 2N Ar); be (75 MHz); 182.2, 161.1, 156.6, 151.8, 150.8, 150.0, 136.1, 128.8, 128.4, 126.4, 
126.0,124.9,124.0, 12l.8, 118.1, 112.5, 109.0,62.4,51.8 (2 x C) and 50.6 (2 x C); LRMS (EI) mlz 
486 [3 %, M+], 260 [100%, M-CI4HISCIN3]; Anal. Caled. for C22HI802BrN4CI'I-bO C 52.4%, H 
3.6%,1\ 11.5%. Found C 52.7%, H 3.5%, N 11.6%. 
E. General procedure for the preparation of compounds 66a-66e 
To a solution of isatin or substituted isatin-3-thiosemicarbazone derivative (0.2g, 1.3611111101) in 5mL 
of 99.9 ethanol was added a mixture of compound 69 (0.22g, 1.36mmol) and aqueous 
formaldehyde 37% (0.027 mL, 1.35mmol) also dissolved in 10mL ethanol (99.9%). The reaction 
mixture was stilTed for 3 hours at room temperature, refrigerated for 48 hours to form crystals. The 











S N 1-/4-(7-Chloro-quillolill-4-yl}-piperazill-J-ylmethyl-l H-illdole-2,3-
N-N ~ NH2 diolle 3-thiosemicarbazolle 
5,(1 J~,~H (0.29g, 78 %) obtained as orange crystals; mp 216-217 °C (from 
. 12 0 
6~-'N1 
7 7a l, 2' 6" ethanol); IR (KBr): vmax/cm- I 3686 (N-H), 3036 (Ar-H), 1675 (C=O), 
~!3o!, 4a":;/ • 7,:CI 1511 (C=N), 1122 (C=S); Oil (300 MHz; DMSO-d6); 12.40 (lH, s, 
2~/1\j 8 
3' 4"11 8a" NNH), 9.04 (lH, s, NHH), 8.69 (111, s, NHH), 8.65 (lH, d, J 5.2, H-
3"~N1" 
66a 
2" 2"), 7.96 (lH, d, J 9.0, H-5/1), 7.91 (lH, d, J 2.4, H-8"), 7.66 (IH, dd, J 
1.2 and 7.6, H-4), 7.48 (IH, dd, J 2.4 and 9.0, H-6"), 7.42 (Ill, ddd, J 
1.2, 7.2 and 8.0, H-6), 7.32 (lH, d, J 7.2, H-7), 7.15 ([ H, ddd, J 0.4, 7.6 and 8.0, H-5), 6.61 (lH, d, J 
5,2, H-3//), 4.60 (2H, s, -NCH2N-), 3.13 (4H, br s, -NCH2CH2NAr), 2.87 (4H, br s, -NCH2CH2NAr); 
0(' (75 MHz); 179.4,162.6,156.9,152.8,150.3, 144.5,134.2,131.8,131.7,128.9,126,8,126.4, 
123.1, 122.1, 121.3, 120.1, 111.7, 110.2,61.7, 52.3 (2 x C) and 50.7 (2 x C); HIL\1S (FAB) m/z 
480.13677 [M+ 1 r, C23H12CI~hOS requires 480.13732; Anal. Ca1cd. for C23H12CIN70S C 57.6%, H 
4.6%, N 20.4%, S 6.7%. Found C 57.6%, H 4.7%, N 20.4%, S 6.8%. 
N1 -(4-(7-Chloro-quinolin-4-yl)-piperazin-l-ylmethyl-5-fluoro-
J H-in dole-2,3-d ion e-3-thiosemicarbazon e 
The conditions employed for the preparation of this compound 
were those described in general procedure E. However, 0.84 
mmol of compound 65d and thiosemicarbazide were used. 
(0.21 51 %) obtained as yellowish-orange crystals; mp 233-234 
°C (from ethanol); IR (KBr): vmax!cm- J 3686 (N-H), 1630(C=O), 
66b 15 11 (C=N), 1121 (C=S); Oil (400MHz;DMSO-d6); 12.31 (1 H, s, 
NNH), 9.15 (lH, s, NHH), 8.81 (lH, s, NHH), 8.67 (lH, d, J 5.4, H-2"), 7.98 (lH, d, J 8.7, H-5"), 
7.93 (lH, d, J 2.4, H-8"), 7.57 (lH, d, J 2.7, H-4), 7.48 (lH, dd, J 2.4 and 8.7, H-6"), 7.38 (IH, dd, J 
2.7 and 7.6, H-6), 7.28 (lH, d, J 7.6, H-7), 6.61 (Ill, d, J 5.4, H-3"), 4.60 (2H, s, -NCH2N-), 3.13 
(4H, br s, -NCH2CH2NAr), 2.88 (4H, br s, -NCH2CH2NAr); <'ic(75 MHz); 178.7, 161.8, 156.6, 152.1, 
149.5,139.8,138.5,133.5,131.3,130.5,127.9,126.1, 125.7, 122.0,121.5,120.2,111.9,109.4, 
61.1,51.6 (2 x C) and 49.9 (2 x C); Anal. Calcd for C23H21 CIFN70S C 55.5%, H 4,3%, N 19.5%, S 
6.4°1<). Found C 55.9%, H 4.2%, N 19.5%, S 5.8%; HRMS (FAB) 171/Z 498.12924 [M+ 1 r 













CI~, 4",3a 13 H 
,I ffO 
~7 N1 7 a 
Experimental 
N 1-[4-{7 -Chloro-quinolin-4-yl)-piperazin-l-ylmethyl-5-
chloro-lH-indole-2, 3-dione 3-thiosemicarbazone 
The conditions employed for the preparation of this compound 
were those described in general procedure E. However, 0.37 
2' 6" 
N~3' 5"'0' 7" CI mmol of compound 65c and thiosemicarbazide were used. 
2~rtt' 4a"i • 8" (0.35g, 86 %) obtained as orange crystals; mp 234-235 °c (from 
3' 43~" I~ ~Ns1a,," 3"~ ethanol); IR (KBr): vmaJcm'1 3687 (N-H), 1675 (C=O), 1518 
2" 
66c (C=N), 1120 (C=S); bH (300 MHz; CDCI 3); 12.3 (1 H, s, NNH), 
9.10 (lH, s, NHH), 8.71 (l H, s, NHH), 8.68 (lH, d, J5.4, H-2"), 8.01 (IH, d, J2.0, H-8"), 7.88 (lH, 
d, J 8.8, H-5"), 7.61 (1 H, d, J 2.1, H-4), 7.59 (l H, dd, J 2.1 and 8.4, H-6), 7.42 (1 H, dd, J 2.0 and 8.8, 
H-6"), 7.11 (lH, d, J 8.4, H-7), 6.81 (IH, d, J 5.4, H-3"), 4.58 (2H, s, -NCH2N-), 3.21 (4H, br S,-
NCH2CH2NAr), 2.91 (4H, br s, -NCH2CH2NAr); be (75 MHz); 178.7, 162.6, 158.3, 156.7, 151.7, 
150.1, 149.5, 138.9, 128.9, 128.4,126.4,125.2,123.9,123.7,121.7,119.1, 111.9, 110.0,62.4,5\.9(2 
x C), 51.2 (2 x C); Anal. Caled. for C23H21CbN70S C 53.8%, H 4.1 %, N 18.6% S 5.8% Found C 
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bromo-l H-indo le-2,3-d ione3-thiosemicarbazone 
The conditions employed for the preparation of this compound 
were those described in general procedure E. However, 0.67 
mmol of compound 65g and thiosemicarbazide were used. 
(O.27g, 73 %) obtained as orange crystals; mp 236-237 °c (from 
ethanol); IR (KBr): vma,.Jcm,l 3688 (N-H), 1628 (C=O), 1515 
(C=N), 1122 (C=S); bH (300 MHz; DMSO-d6); 12.24 (1 H, s, 
NNH), 9.14 (IH, s, NHH), 8.87 (IH, s, NHIJ), 8.69 (IH, d, J 
5.4, H-2"), 7.97 (1 H, d, J 9.0, H-5"), 7.91 (1 H, d, J2.4, H-8"), 7.62 (1 H, d, J, 2.1, H-4), 7.50 (IH, dd, 
J2.! and 7.8, H-6), 7.39 (tH, dd,J2.4 and 9.0, H-6"), 7.35 (tH, d,J7.8, H-7), 6.69 (IH, d,J5.4, H-
3"),4.67 (2H, s, -NCH2N-), 3.15 (4H, br s, -NCH2CH2NAr), 2.89 (4H, br s, -NCH2CI-hN-); be (75 
MHz); 179.5,161.8,156.9,152.1,149.5,143.7 , 133.5,131.6,131.0,130.9,127.9,126.1,125.7, 












[M+ It C23 H2I BrCIN60S requires 558.04784; Anal. Caled. for C23H2I BrCIN70S C 49.4%, H 3.8%, 
N 17.0%, S 5.7% Found C 50.2%, H 3.9%, N ] 7.2%, S 5.1 %. 
66e 
N 1_ [4-(7 -Chloro-q u inolin-4-yl)-piperazin-l-ylmethyl-methyl-
IH-indole-2,3-dione-3-thiosemicarhazone 
'rhe conditions employed for the preparation of this compound 
were those described in general procedure E. However, 0.85 
mmol compound 65e and thiosemicarbazide were used. 
(0.33g, 78%) obtained as yellowish-orange crystals; mp 232-234 
°c (from ethanol); IR (KBr): Vmax/cm- I 3687 (N-H), 1675 (C=O), 
1518 (C=N), 1122 (C=S); Oll (300 MHz; DMSO-d6); 12.37 (l H, s, 
NNH), 9.17 (IH, s, NHH), 8.91 (IB, s, NHH), 8.68 (lH, d,J5.4, 
B-2"), 7.99 (J H, d, J 9.0, H-5"), 7.94 (I H, d, J 2.1, H-8"), 7.78 
(IB, d, J2.1, H-4), 7.55 (lH, dd, J2.l and 8.7, B-6), 7.48 (lB, d, J2.1 and 9.0, B-61/), 7.34 (IB, d,J 
8.7, B-7), 6.69 (IH, d, J 5.4, B_31/), 4.81 (2H, s, -NCH2N-), 3.16 (4H, br s, -NCH2CH2NAr), 2.90 
(4H, br s, -NClhCH2NAr), 2.27 (3H, s, Ar-Clh); Oc (75 MHz); 179.4, 161.7, 156.2, 152.8, 149.5, 
144.0,142.4,134.6,132.0,130.8,127.9,126.1,125.0, 123.6,121.3,120.0,112.3, ]09.4, 63.1,51.6 
(2 x C), 49.5 (2 x C) and 21.3; HRMS (FAB) mlz 494.15187 [M+lt C24H24CIN70S requires 
494.15297; Anal. for Calcd. C24H24C1N70S C 58.4%, H 4.9%, N ] 9.8%, S 6.5%. Found C 58.4 %, 
H4.9 %, N19.7 %, S 6.2%. 
F. General procedure for preparation of compounds 70a-70f 
Equimolar quantities ofisatin-3-thiosemicarbazone (0.20g, 0.91 mmol), amine (0.09 mL, 0.9\ mmol) 
and paraformaldehyde (0.08g, 0.90mmol) were dissolved in warm 99.9 % ethanol. The mixture was 
continuously stirred at 25°C for 6 hours. After standing for approximately 24 hours in the fridge, a 
crystalline product was formed. The product was then separated by filtration, vacuum dried and 
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N 1-Diethylaminomethyl-indole-2, 3-dione-3-thiosemicarbazone 
(0,l5g, 54%) obtained as yellow crystals; mp 134-135 °c (ethanol) (lit 135 
0c) [160]; oH (300MHz; DMSO-d6); 12.10 (lH, s, NNH), 9.05 (IH, s, NHH), 
8.69 (IH, s, NHH), 7.71 (IH, dd,JO.9 and 7.5, H-4), 7.44 (JH, ddd,JO.9, 6.6 
and 8.0, H-6), 7.17 (lH, ddd,JO.9, 6.6 and 7.5, H-5), 7.19 (IH, d,J8.0, H-7), 
4.52 (2H, s, -NCH2N-), 2.65 (4H, g, J 6.9, -NCH2CH3), 1.06 (6H, t, J 6.9, -
NCH2CH3). 
N 1-Piperidin-l-ylmethyl-indole-2, 3-dione-3-thiosemicarbazone 
(0.27g, 95%); obtained as yellow solids; mp 179-180 °c (from ethanol) (lit 
174°C) [160]; OH (300 MHz, DMSO-d6); 12.38 (lH, s, NNH), 9.05 (tH, s, 
NHH), 8.69 (lH,s, NHH), 7.71 (lH, dd, JO.9 and 7.5, H-4), 7.41 (IH, ddd, 
JO.9, 7.8 and 8.1, H-6), 7.26 (lH, d, J 7.8, H-7), 7,17(lH, ddd, J 1.2,7.5 
and 8.1, H-5), 4.47 (2H, s, -NCH2N-), 2,54 (4H, t, J 4.8, H-2'), 1.46 (4H, m, 
H-3' 3'), 1.33 (2H, m, H-4' 4'); 
70c 
2'), 1,65 (4H, m, H-3'). 
N1-Pyrrolidin -1-ylmethyl-indole-2, 3-dione-3-thiosemicarbazone 
(0.25g, 90%) obtained as yellow crystals; mp 181-184 °c (from ethanol) 
(lit 177-178 °C) [160]; 011 (400 MHz, DMSO-d6); 12,29 (lH, s, NNH), 9.03 
(IH, s, NHH), 8.68 (IH, s, NHH), 7.68 (lH, dd, J 1.2 and 7.6, H-4), 7.42 
(lH, ddd, J 1.2,7.2 and 8.0, H-6), 7.23 (IH, d, J 8.0, H-7), 7.12 (lH, ddd, 













N1-Morpholin-4-y Imethyl-indole-2, 3-d ione-3-thiosemicarbazone 
(0.27g, 92 %); as yellow crystals; mp 208-210 °c (from ethanol) (lit 215-
216°C) [160]; 8H (300MHz; DMSO-d6); 12.37 (lH, s, NNH), 9.0S (lH, s, 
NHH), 8.70 (lH, s, NHH), 7.72 (lH, dd, J 0.6 and 7.2, H-4), 7.42 (lH, 
ddd, J 0.9,7.5 and 8.0, H-6), 7.27 (lH, d, J 8.0, H-7), 7.1S (IH, ddd, J 
0.6, 7.2 and 7.S, H-S), 4.49 (2H, s, -NCH2N-), 3.S4 (4H, br S, H-3'),2.57 
(4H, br S, H-2'). 
N 1_( 4-Benzyl-piperazin-l-ylmethyl-indole-2,3 -dione-3-
thiosemicarbazone 
(0.23g, 63%); obtained as yellow crystals; mp 187-188 DC; lR (KBr): 
Vmax/cm'] 3680 (N-H), 3428 (N-H), 1637 (C=O), IS0S (C=N), 1123 
(C=S); ()H (300 MHz, DMSO-d6); 12.38 (IH, s, NNH), 9.06 (lH, S, 
NHH), 8.69 (lH, s, NHH), 7.71 (Ill, dd, J 0.9 and 7.5, H-4), 7.43 (I H, 
ddd, J 0.9,7.2 and 7.8, H-6), 7.2S-7.23 (SH, m, H-2/1, H-3/1, H-4", H-S" 
and H-6"), 7.19 CI H, d, J 7.8, H-7), 7.17 (lH, ddd, J 0.6, 7.2 and 7.S, H-
5), 4.52 (2H, s, -NCH2N-), 3.43 (2H, s, -NCH2Ar), 2.59 (4H, br s, -
NCH2CH2NCH2Ar), 2.34 (4H, br s, -NCH2CH2NCH2Ar); oe (75 MHz); 
178.7,161.6,143.7,138.2,131.0,130.9,128.6 (2 x C), 128.0,126.8 (2 x C), 122.8, 120.5,119.2, 
111.1,61.8, S2.3 (2 x C), 50.1 (2 x C) and 49.9; Anal. Calcd. for C21 H24N60S; C 62.1%, H 6.6%, N 
20.1%, S 6.6 Found C 61.7%, H 5.9%, N 20.6%, S 6.6%; HRMS (FAB) mlz 409.18109 [M+lt, 
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(0.27g, 76%) obtained yellowish crystals; 188-191 DC; IR (KBr): 
vmax/cm'l 3686 (N-H), 3575 (N-H), 1694 (C=O), 1502 (C=N), 1127 
(C=S); 8H (300 MHz, DMSO-d6); 12.39 (1 H, s, NNH), 9.04 (1 II, S, 
NHH), 8.69 (lH, s, NHH), 7.79 (lH, dd, JO.9 and 7.6, H-4), 7.45 (IH, 
ddd, J 0.9, 6.6 and 8.0, H-6), 7.18 (1 H, d, J 8.0, H-7), 7.21-7.13 (SH, 












(2H, s, -NCH2N-), 3.09 (4H, br s, -NCH2CH2NAr), 2.76 (4H, br s, -NCH2CH2NAr); Or (75 MHz); 
178.7, 161.7,151.0,143.7,131.1,130.9,128.8,122.0,120.6 (2 x C), 120.5, 119.3 (2 x C), 119.2, 
111.1,60.9,50.1 (2 x C) and 48.1 (2 x C); Anal. Calcd. for C2oH22N60S C 60.9%, H 5.6%, N 21.3%, 
S 8.1% Found C 61.3%, H 6.3%, N 18.7%, S 5.7%; HRMS (FAB) mlz 395.16544 (M+lt, 
C2oH22N60S requires 395.16541 
G. General procedure for the preparation of compounds 71 
Equimolar quantities of ethyl-quinoline isatin derivative (O.lg, 0.284 mmoJ) and thiosemicarbazide 
(0.038g, 0.284mmo\) were dissolved in warm 99.9 % ethanol. The mixture was then continuously 
stirred at 45 DC for 5-6 hours. After standing for approximately 24 hours at room temperature, a 
crystalline product was formed. The product was then separated by filtration, vacuum dried and 




(0.08g, 70%) obtained as orange crystals; mp 167-171 DC (from 
acetonitrile); IR (KBr): vrnnx!cm'l 3680 (N-H), 3404 (N-H), 3012 (Ar-
H), 1635 (C=O), 1516 (C=N), 1140 (C=S); 011 (400MHz, DMSO-d6); 
12.31 (lH, s, NNH), 9.02 (lH, s, NHH), 8.67 (IH, s, NHH), 8.40 (IH, 
d, J 5.4, H-2"), 7.98 (1 H, d, J 9.0, H-5"), 7.76 (l H, d, J 2.0, H-8"), 
7.67(1 H, dd, J 0.6 and 7.4, H-4), 7.38 (1 H, dd, J 2.0 and 9.0, H-611 ), 
71a 7.28 (1H, ddd, J 0.6,7.6 and 7.8, H-6), 7.10 (1 H, ddd, J 0.9,7.4 and 
7.6, H-5), 7.02 (1 H, d, J 7.8, H-7), 6.63 (1 H, d, J 5.4, H-3"), 4.01 (2H, t, J 5.6, -CH2CH2NHAr), 3.65 
(2H, t,J5.6, -CH2CH2NHAr); oc(75 MHz); 179.4,161.8,152.6,150.5,149.7,149.1,143.7,138.6. 
134.1,128.2,124.9,124.5,123.7,123.1,118.2,117.3, 110.3, 104.5,74.9 and 42.4; HRMS (FAB) 
Found mlz 425.09419 [M+ It, C2oH17CIN60S] requires 425.09513; Anal. Calcd. for C2oH17CIN60S· 













N 1-!2-(7-Chloro-q uinolin-4-ylamino )-eth yl/-5-methyl-1 H-indole-2,3-
dione-3-thiosemicarbazone 
The conditions employed for the preparation of this compound were 
those described in general procedure G. However, 0.27 mmol of 
compound 75b and thiosemicarbazide were used. 
(O.IIg, 89 %) obtained as yellow-orange crystals; mp 227-230 °c (from 
ethanol); IR (KBr): vmax!cm-1 3632 (N-H), 3378 (N-H), } 665 (C=O), 
1506 (C=N), 1 J 27 (C=S); OH (400MHz; DMSO-d6); 12.29 (1 H, s, 
NNH), 8.98 (l H, s, NHH), 8.63 (1 H, s, NHH), 8.40 (1 H, d, J 5.6, H-2"), 
8.01 (IH, d, J9.0, H-5"), 7.76 (lH, d, J2.0, H-8"), 7.49 (lH, d, J2.0, H-4), 7.39 (lH, dd, J2.0 and 
9.0, H-6"), 7.08 (lH, dd, J 2.0 and 7.4, H-6), 7.00 (1 H, d, J 7.4, H-7), 6.60 (l H, d, J 5.6, H-3"), 3.98 
(2H, t, J 5.4, -NCH2CH2NHAr), 3.62 (2H, t, J 5.4, -NCH2CH2NHAr), 2.31 (3H, s, Ar-Clh); Dc (75 
MHz); 179.4, 161.8, 152.5, 150.6, 149.7 149.0, 141.6, 138.9, 134.2, 128.1, 125.3, 124.9, 124.5, 
121.9, 118.2, 118.1, 110.9, 110.6,74.9,41.8 and 21.2; LRMS (FAB) mlz 439 [5 %, (M+ltL and 
307 [30 %, M-C1SH14CIN3]; Anal. Caled. for C21 H19CIN60S; C 57.5%, H 4.4%, N 19.3%, S 7.3% 
Found C 57.1 %, H 4.3%, N 18.8%, S 7.3%. 
S 
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71e 
N 1-/2-(7-Chloro-quinolin-4-ylamino)-ethyl/-5-chloro-1 H-indole-2, 
3-dione 3-thiosemicarbazone 
The conditions employed for the preparation of this compound were 
those described in general procedure G. However, 0.26 mmoJ of 
compound 75e and thiosemicarbazide were used. 
(0.16g, 68 %) obtained as orange crystals; mp 221-227 °C (from 
ethanol); IR (KBr): vmax!cm- 1 3688 (N-H), 3478 (N-H), 1665 (C=O), 
1510 (C=N), 1121 (C=S); OH (400MHz, DMSO-d6); 12.29 (lH, s, 
NNH), 8.98 (1 H, s, NHH), 8.64 (1 H, s, NHH), 8.40 (l H, d, J 5.0, H-
2"), 8.01 (l H, d, J 9.0, B-5"), 7.76 (1 H, d, J 2.1, B-8"), 7.49 (1 H, d, J 2.0, H-4), 7.39 (1 H, dd, J 2.0 
and 9.0, H-6"), 7.09 (lH, dd, J 2.0 and 7.4, H-6), 7.01 (lH, d, J 7.4, H-7), 6.60 (lH, d, J 5.0, H-3"), 
3.98 (2H, t, J 6.4, -NCH2CH2NIIAr), 3.62 (2H, t, J 6.4, -NCH2CH2NHAr); Dc (75 MHz); 178.3, 
158.2, 151.9, 150.8, 149.8, 149.0, 142.1, 136.7, 127.5, 127.3, 124.8, 124.2, 123.5, 121.9, 117.6, 












required 459.05615; Anal. Calcd. for C2oH16ChN60S, C 57.5%, H 4,4%, N 19.3%, S 7.3%. Found C 





3' I ~4a' ~ 6' 
2-(7-Chloro-quinolin-4-ylaminoj-ethanol 
A mixture of 4, 7-dichloroquinoline (4.0g, 20.19 mmol), ethanolamine 
(24,42mL, 403.9mmol) and triethylamine (0.84mL, 6.06 mmol) was stirred 
under reflux for 8 hours. The reaction mixture was then cooled to room 
0' / ~ 7' 
~ 8a' 8' CI temperature during which a white precipitate formed. The precipitate was 
73 filtered, washed with water (3 x 50mL) and recrystallized from methanol to 
obtain (4.lOg, 92 %) as cream-white crystals, mp 213-215 °C (from methanol) (lit 214°C) [161]; Rf 
0.42 (MeOH/DCM, 2:8); 8H (300MHz; CD30D); 8.35 (1 H, d, J 6.0, H-2'), 8.09 (1 H, d, J 9.0, H-5'), 
7.78 (1 H, d, J 2.1, H-8'), 7,40 (nl, dd, J 2.1 and 9.0, H-6'), 6.57 (l H, d, J 6.0, H-3'), 3.86 (2H, t, J 
5.7, ArNHClhClh-), 3.52 (2H, t, J 5.7, ArNHCH2-); 8c(75 MHz); 151.8, 150.1, 149.0, 133.3, 127.4, 
123.9, 117.4, 108.6,58.7 and 45.0; LRMS (EI) mlz 223.1 [ M+,]; AnaL Calcd C 59.3%, H 4.9%, N 
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Methanesulfonic acid 2-(7-chloro-quinolin-4-ylaminoj-ethyl ester 
A solution of compound 73 (8.0g, 36 mmol) in 24 mL of pyridine was stirred 
at O°C for 30 minutes. Whilst at 0 °C methanesulfonyl chloride (6.97mL, 90.0 
mmol) in 22mL of pyridine was added slowly to the above solution, and the 
resultant mixture stirred for 5 hours. The reaction mixture was then diluted 
with 17% aqueous ammonia solution (25 mL), extracted with CH2Cb (3 x 50 
mL), dried over anhydrous MgS04, concentrated and recrystallized from 
74 methanol! water to obtain yield (8.96g, 83%) obtained as white crystals, mp 
138-140 °C (from MeOH I H20), RfO.76 (MeOH/DCM, 2:8); IR (KBr) vmaxlcm-1; 3218 (N-H), 1579 
(C=N), 1442(C=C); 8H (300MHz; CD30D); 8.39 (I H, d, J 5.7, H-2'), 8.08 (lH, d, J 9.0, H-5'), 7.79 
(IH, d,J2.1, H-8'), 7.41 (tH, dd,J2.1 and 9.0, H-6'), 6.61 (lH, d,J5.7, H-3'), 4,48 (2H, t,J5.4, 
ArNHCH2CH2-), 3.74 (2H, t, J, 5,4, ArNHCH2-) 3.07 (3H, s, -OS02-CH3); 8c (100 MHz); 151.9, 
150.2,149.1, \33.2, 127.8, 124.1, 123.9, 117.9, 108.0,66.8,42.4 and 37.8; HRMS (EI) Found mlz 
300.03487 [Mt, CI2H1303CIN2S requires 300.03354; Anal. Calcd. for C J2H 130 3N2SCI C 47.9%, H 












H. General procedure for preparation compounds 75a-75e 
To a mixture of isatin or substituted isatin (0.1 g, 0.68 mmol) in 10 mL of anhydrous DMF at 0 °c 
was added NaH (0.02g, 0.815 mmol) was then added to this mixture followed by Compound 74 
(0.27g, 0.88 mmol) warming to room temperature with stirring over I hour. The temperature was 
then raised to 60°C and stirring continued for a further 12 hours. Ice-cold water was added to the 
reaction and a coloured precipitate formed. The solid was filtered, washed with water (2 x 25 mL), 
petroleum ether (l x 1 OmL) and dried under vacuum to give the desired product. 
N 1-/2-(7-Chloro-q uinolin-4'-ylamino)-ethylJ-lH-indole-2, 3-dione 
(0.21g, 88%) obtained as orange crystals; mp 240-243 °c (from 
methanol); Rr 0.43 (MeOH: EtOAc, 2:8); IR (CHCh) vmax!cm- I 3236 
(N-H), 1734 (keto C=O), 1600 (amide C=O), 1514 (C=N); OH 
(300MHz; DMSO-d6); 8.41 (tH, d, .I 5.4, H-2/1), 7.97 (lH, d, .I 9.0,11-
5"),7.76 (lH, d, .I 2.4, H-8/1), 7.52 (tH, dd, .I 0.6 and 7.2, H-4), 7.48 
(1 H, ddd, .I 0.6, 6.6 and 7.4, H-6), 7.39 (1 H, dd, .I 2.4, 9.0, H-6/1), 7.07 
75a (lH, ddd, .I 0.9,6.6 and 7.2, H-5), 7.03 (lH, dd, .I 0.9 and 7.4, 11-7), 
6.62 (lH, d, .I 5.4, H-3/1), 3.93 (2H, t, .I 5.l, ArNHCH2CH2-), 3.60 (2H, t, .I 5.1, ArNHCH2-); Oc (75 
MHz); 183.3, 158.3, 151.9, 150.6, 149.7, 149.0, 137.8, 133.3, 127.4, 124.3, 124.0, 123.7, 122.9, 
117.4, 117.0, 110.2, 104.6, 74.9 and 42.0; HRMS (FAB) Found mlz 352.08494 [M+I]\ 
C19H1402N3Cl] requires 352.08527; Anal. Calcd. for C19HI402N3CI C 64.8%, H 4.0%, N 11.9%. 
Found C 64.4%, H 3.9%, N 11.2%. 
NH 
4" 5" 
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~ I 7" 
2" ~N Sa" ~ • CI 
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75b 
N J -/2-(7-Chloro-q uinolin-4-ylamino)-ethylJ-5-methyl-l H-indole-2, 
3-dione 
The conditions employed for the preparation of this compound were 
those described in general procedure H. However, 0.62 mmol of isatin 
and 0.81 mmol of compound 74 were used. 
0.62 mmol, (O.l6g, 68 %) obtained as red crystals; mp 240-243 °C 
(from methanol); Rr 0.28 (MeOH: EtOAc; 2:8); IR (KBr) vmax!cm- I 
3236 eN-H), 1737 (keto C=O), 1600 (amide C=O), 1514 (C=N); OH 
(300MHz; CDC b); 8.53 (l H, d, .I 5.4, H-2/1), 7.93 (1 H, d, .12.4, H-8/1), 












2.4 and 9.0, H-6"), 6.81 (IH, d, J 7.2, H-7), 6.62 (lH, d, J 5.4, H-3/1), 4.15 (2H, t, J 5.4 , 
ArNHCH2CH2-), 3.67 (2B, t, J 5.4, ArNHCH2-), 2.32 (3H, s, Ar-CH3); Oc (75 MHz), 183.6, 158.2, 
152.0, 150.5, 149.7, 149.1, 137.7, 133.4, 126.8, 124.6 , 124.2, I .4, I .1, 117.5, 116.9, 111.2, 
104.6, 74.6, 42.1 and 20.3; LRMS (EI) mlz 365.0 [16 %, MI], 191 [100 %, M-C IOBgClN2]; Anal. 
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5-Chloro-N1- [2 -(7-chloro-quinolin-4'-ylamino)-ethyIJ-l H-indole-2, 
3-dione 
The conditions employed for the preparation of this compound were 
those described in general procedure H. However, 0.55 mmol of isatin 
and 0.72 mmol of compound 74 were used. 
(O.15g, 69%) obtained as orange crystals; mp 221-223 °c (from 
ethanol); Rf 0.46 (MeOH; EtOAc, 2:8); IR (CHCb) vmax/cm'l. 3237 
75c (N-H), 1734 (C=O), 1606 (amide C=O), 1519 (C=:.J); OH (300M Hz; 
DMSO-d6); 8.43 (1 H, d, J 5.4, H-2"), 7.94 (I H, d, J 8.4, H-5/1), 7.78 (1 H, d, J I, H-8"), 7.59 (1 H, d, 
J 2.4, H-4), 7.40 (l H, dd, J 2.4 and 8.7, H-6), 7.31 (l H, dd, J 2.1 and 8.4, H-6"), 7.07 (l H, d, J 8.7, 
H-7), 6.64 (lH, d, J 5.4, H-3"), 3.96 (2H, t, J 5.4, ArNHClhCH2-), 3.64 (2H, t, J 5.4, ArNHClh-); Oc 
(75 MHz); 182.3, 158.2, 151.9, 150.7, 149.8, 149.0, 136.7, 127.4, 127.2, 124.8, 124.2, 123.4, 121.9, 
117.5, 117.0, 109.7, 104.7, 74.6 and 42.3; HRMS (FAB) Found mlz 386.04642 [M+lt 
CI9H1302N3Ch requires 386.04630; Anal. Calcd. for C'9HI302N3Cb C 59.1 %, H 3.4 %, N 10.9 %. 
Found C 59.0 %, H 3.4 %, N 10.8 %. 
N 1-[2-(7-Chloro-q uinolin-4-ylamino )-ethyIJ-5, 7-dimethyl-1H-
indole-2, 3-dione 
The conditions employed for the preparation of this compound were 
those described in general procedure H. However, 0.57 mmol of isatin 




a" -"'::::." (0.19g, 89%) obtained as orange crystals; mp 219°C (from ethanol); 
10" 
o"~~
- ~ 8a" 8" CI Rr 0.53; IR (CHCI3) Vmax fcm" 3236 (N-H), 1736 (keto Cc=:O), 1607 
75d (amide C=O), 15] 9 (C=N); OH (300MHz; DMSO-d6); 8.40 (1 H, d, J 
5.4, H-2"), 8.03 (1 H, d, J 9.0, H-5"), 7.78 (lH, d, J2.1, H-8"), 7.44 (I H, d, J2.4, H-4), 7.40 (1 H, d, J 











ArNHCH2CHr ), 3.64 (2H, t, J 6.3, ArNHCH2-), 2.40 (3H, s, Ar-CH3), 2.22 (3H, s, Ar-CH3); be (75 
MHz); 182.2, 158.6, 151.8,150.4,149.8,149.0,136.3,127.5,127.4,124.1, 123.7, 122.7, 121.2, 
117.8, 117.4, 110.6,104.6,74.3,42.7,19.8 and 18.2; HRMS (FA B) Found mlz 380.11717 [M+lf 
C21HI802N3CI requires 380.11657; Anal. Calcd. for C2lHl802N3CI C 66.4%, H 4.7%, N 11.1 %. 
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